<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">World J. Gastroenterol</journal-id><journal-id journal-id-type="publisher-id">WJG</journal-id><journal-title-group><journal-title>World Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">1007-9327</issn><issn pub-type="epub">2219-2840</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29904241</article-id><article-id pub-id-type="pmc">PMC6000297</article-id><article-id pub-id-type="other">jWJG.v24.i22.pg2327</article-id><article-id pub-id-type="doi">10.3748/wjg.v24.i22.2327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Microbial markers in colorectal cancer detection and/or prognosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vill&#x000e9;ger</surname><given-names>Romain</given-names></name><aff>Universit&#x000e9; Clermont Auvergne, Inserm U1071, USC-INRA 2018, M2iSH, CRNH Auvergne, Clermont-Ferrand 63000, France</aff></contrib><contrib contrib-type="author"><name><surname>Lop&#x000e8;s</surname><given-names>Am&#x000e9;lie</given-names></name><aff>Universit&#x000e9; Clermont Auvergne, Inserm U1071, USC-INRA 2018, M2iSH, CRNH Auvergne, Clermont-Ferrand 63000, France</aff><aff>Research Biologics, Sanofi R&#x00026;D, Vitry-Sur-Seine 94400, France</aff></contrib><contrib contrib-type="author"><name><surname>Veziant</surname><given-names>Julie</given-names></name><aff>Universit&#x000e9; Clermont Auvergne, Inserm U1071, USC-INRA 2018, M2iSH, CRNH Auvergne, Clermont-Ferrand 63000, France</aff><aff>Chirurgie digestive, Centre Hospitalier Universitaire, Clermont-Ferrand 63000, France</aff></contrib><contrib contrib-type="author"><name><surname>Gagni&#x000e8;re</surname><given-names>Johan</given-names></name><aff>Universit&#x000e9; Clermont Auvergne, Inserm U1071, USC-INRA 2018, M2iSH, CRNH Auvergne, Clermont-Ferrand 63000, France</aff><aff>Chirurgie digestive, Centre Hospitalier Universitaire, Clermont-Ferrand 63000, France</aff></contrib><contrib contrib-type="author"><name><surname>Barnich</surname><given-names>Nicolas</given-names></name><aff>Universit&#x000e9; Clermont Auvergne, Inserm U1071, USC-INRA 2018, M2iSH, CRNH Auvergne, Clermont-Ferrand 63000, France</aff><aff>Universit&#x000e9; Clermont Auvergne, Institut Universitaire de Technologie de Clermont-Ferrand, Clermont-Ferrand 63000, France</aff></contrib><contrib contrib-type="author"><name><surname>Billard</surname><given-names>Elisabeth</given-names></name><aff>Universit&#x000e9; Clermont Auvergne, Inserm U1071, USC-INRA 2018, M2iSH, CRNH Auvergne, Clermont-Ferrand 63000, France</aff><aff>Universit&#x000e9; Clermont Auvergne, Institut Universitaire de Technologie de Clermont-Ferrand, Clermont-Ferrand 63000, France</aff></contrib><contrib contrib-type="author"><name><surname>Boucher</surname><given-names>Delphine</given-names></name><aff>Universit&#x000e9; Clermont Auvergne, Inserm U1071, USC-INRA 2018, M2iSH, CRNH Auvergne, Clermont-Ferrand 63000, France</aff><aff>Universit&#x000e9; Clermont Auvergne, Institut Universitaire de Technologie de Clermont-Ferrand, Clermont-Ferrand 63000, France</aff></contrib><contrib contrib-type="author"><name><surname>Bonnet</surname><given-names>Mathilde</given-names></name><aff>Universit&#x000e9; Clermont Auvergne, Inserm U1071, USC-INRA 2018, M2iSH, CRNH Auvergne, Clermont-Ferrand 63000, France</aff><aff>Universit&#x000e9; Clermont Auvergne, Institut Universitaire de Technologie de Clermont-Ferrand, Clermont-Ferrand 63000, France. <email>mathilde.bonnet@uca.fr</email></aff></contrib></contrib-group><author-notes><fn><p>Author contributions: Vill&#x000e9;ger R, Lop&#x000e8;s A, Veziant J, Gagni&#x000e8;re J, Billard E and Boucher D organized and wrote the manuscript; Barnich N critically revised the manuscript; Bonnet M organized, wrote and supervised the writing of the manuscript.</p><p>Supported by <funding-source>Inserm and Universit&#x000e9; Clermont Auvergne</funding-source> (<award-id>UMR 1071</award-id>), <funding-source>INRA</funding-source> (<award-id>USC-2018</award-id>); and grants from <funding-source>&#x0201c;Conseil regional Auvergne-Rhones-Alpes&#x0201d;</funding-source>and <funding-source>FDER/CPER</funding-source>.</p><p>Correspondence to: Mathilde Bonnet, PhD, Assistant Professor, M2iSH &#x0201c;Microbes, Intestin, Inflammation et Susceptibilit&#x000e9; de l&#x02019;H&#x000f4;te&#x0201d; UMR 1071 Inserm/Universit&#x000e9; d&#x02019;Auvergne USC INRA 2018, Centre Biom&#x000e9;dical de Recherche et Valorisation, 28 Place Henri Dunant, Clermont-Ferrand 63000, France. <email>mathilde.bonnet@uca.fr</email></p><p>Telephone: +33-4-7318381 Fax: +33-4-73178371</p></fn></author-notes><pub-date pub-type="ppub"><day>14</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>14</day><month>6</month><year>2018</year></pub-date><volume>24</volume><issue>22</issue><fpage>2327</fpage><lpage>2347</lpage><history><date date-type="received"><day>6</day><month>4</month><year>2018</year></date><date date-type="rev-recd"><day>3</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9;The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><abstract><p>Colorectal cancer (CRC) is the second leading cause of cancer worldwide. CRC is still associated with a poor prognosis among patients with advanced disease. On the contrary, due to its slow progression from detectable precancerous lesions, the prognosis for patients with early stages of CRC is encouraging. While most robust methods are invasive and costly, actual patient-friendly screening methods for CRC suffer of lack of sensitivity and specificity. Therefore, the development of sensitive, non-invasive and cost-effective methods for CRC detection and prognosis are necessary for increasing the chances of a cure. Beyond its beneficial functions for the host, increasing evidence suggests that the intestinal microbiota is a key factor associated with carcinogenesis. Many clinical studies have reported a disruption in the gut microbiota balance and an alteration in the faecal metabolome of CRC patients, suggesting the potential use of a microbial-based test as a non-invasive diagnostic and/or prognostic tool for CRC screening. This review aims to discuss the microbial signatures associated with CRC known to date, including dysbiosis and faecal metabolome alterations, and the potential use of microbial variation markers for non-invasive early diagnosis and/or prognostic assessment of CRC and advanced adenomas. We will finally discuss the possible use of these markers as predicators for treatment response and their limitations.</p></abstract><kwd-group><kwd>Colorectal cancer</kwd><kwd>Microbiota</kwd><kwd><italic>F. nucleatum</italic></kwd><kwd>Colibactin-producing <italic>E. coli</italic></kwd><kwd>Prognostic markers</kwd><kwd>Diagnostic markers</kwd><kwd>Dysbiosis</kwd></kwd-group></article-meta></front><body><p><bold>Core tip:</bold> Many clinical studies have reported a disruption in the gut microbiota balance and in the faecal metabolome in colorectal cancer. In this review, we describe the modifications in the microbiota composition and metabolome observed in colorectal cancer (CRC) tissue and stool samples. Then, we detail how these microbiota modifications may represent novel and promising non-invasive diagnostic and/or prognostic markers for CRC and advanced adenoma.</p><sec><title>INTRODUCTION</title><p>Approximately 5% of the population in Western countries will develop colorectal cancer (CRC) during their lifetime[<xref rid="B1" ref-type="bibr">1</xref>]. CRC is a heterogeneous disease with a wide range of long-term outcomes and responses to treatment. Despite recent advances in the genetic and molecular characterization of tumours, CRC remains associated with a poor prognosis and very low rates of long-term survival among patients with advanced disease[<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>]. On the contrary, the 5-year survival of patients treated during the early stages of CRC, which represent only one-third of all CRC patients, is encouraging, ranging from 72% to 100%[<xref rid="B4" ref-type="bibr">4</xref>]. Therefore, early detection of both premalignant lesions and CRC is crucial for increasing the chances of a cure[<xref rid="B5" ref-type="bibr">5</xref>]. Moreover, accurate determination of the prognosis is crucial for the practitioners, in order to optimize and personalize treatment strategies. Given the poor prognosis of this cancer, it is essential to validate new diagnostic and prognostic markers. Studies on the implications of the gut microbiota in CRC are now increasing[<xref rid="B6" ref-type="bibr">6</xref>-<xref rid="B11" ref-type="bibr">11</xref>]. Identification of a CRC-associated dysbiosis and/or the targeted detection of procarcinogenic bacterial species and/or their effectors in stool or tissue samples may represent promising tools to overcome the limitations and the poor performance of current CRC screening tools and prognostic/predictive factors. This review will focus on gut microbiota-related markers, which may be new biological markers for CRC screening or prognosis determination.</p></sec><sec><title>CURRENT STRATEGIES FOR CRC SCREENING AND PROGNOSTIC FACTORS</title><sec><title>Screening strategies</title><p>Individual (opportunistic) and population-based (organized) screening strategies have been established permitting the reduction of CRC mortality either by detecting CRC or removing premalignant lesions[<xref rid="B12" ref-type="bibr">12</xref>]. Several CRC screening tests have been used and have different degrees of performance that vary worldwide and are primarily driven by costs, lifestyle and endoscopic resource constraints. In addition to the classic invasive endoscopic approaches, there has been great interest in developing and evaluating non-invasive methods, including radiographic examinations and stool- and blood-based tests, with the goal of creating efficient, safe, convenient and cost-effective screening tools[<xref rid="B13" ref-type="bibr">13</xref>-<xref rid="B18" ref-type="bibr">18</xref>].</p><p>Endoscopy is currently the most effective modality for detecting asymptomatic premalignant polyps and CRC and for preventing CRC development by the immediate removal of premalignant lesions[<xref rid="B13" ref-type="bibr">13</xref>]. However, this procedure requires prior bowel cleansing and causes postprocedural discomfort, which are both responsible for low participation rates in colonoscopy CRC screening programmes[<xref rid="B13" ref-type="bibr">13</xref>]. Moreover, the need for general anaesthesia and the invasiveness of the procedure exposes patients to potentially severe complications[<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>]. Computed tomography (CT) colonography, also known as &#x0201c;virtual colonoscopy&#x0201d;, is a non-invasive alternative to colonoscopy[<xref rid="B21" ref-type="bibr">21</xref>-<xref rid="B23" ref-type="bibr">23</xref>]. However, CT colonography presents some drawbacks such as its high cost, lack of standardized methods, need for bowel cleansing, poor performance for detecting small or flat lesions, and lack of ability to perform immediate biopsy[<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B24" ref-type="bibr">24</xref>]. For these reasons, other non-invasive stool- and blood-based tests are more promising tools for initial CRC screening in two-step approaches.</p><p>Non-invasive stool-based early CRC screening modalities involve either detecting occult bleeding in the stool, such as with guaiac fecal occult blood test (gFOBT) and faecal immunohistochemical testing (FIT), or detecting DNA, RNA and protein markers of neoplasia in faeces. The rationale for the use of such tools is that the mucosa of both polyps and CRC is more fragile and vascularized and thus bleeds and desquamates more easily than normal colonic mucosa. The effectiveness of gFOBT and FIT have been established for reducing both CRC incidence and mortality, thus permitting their use in many CRC screening programmes[<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B25" ref-type="bibr">25</xref>-<xref rid="B36" ref-type="bibr">36</xref>]. However, these techniques have been criticized for their relatively low specificity[<xref rid="B14" ref-type="bibr">14</xref>]. Therefore, new molecular CRC screening methods targeting abnormal proteins or mRNA expression (<italic>e.g</italic>., <italic>PKM2</italic>, &#x003b2;-actin expression), gene mutations (<italic>e.g</italic>., <italic>KRAS</italic>, <italic>APC</italic>, <italic>P53</italic>), microsatellite instability (MSI) or aberrantly methylated promoter regions present in stool or body fluids are a developing area of investigation to establish innovative large-scale screening programmes[<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B37" ref-type="bibr">37</xref>-<xref rid="B45" ref-type="bibr">45</xref>]. As many tissues release some of their constituents in the bloodstream, the detection of circulating tumour cells DNA (cfDNA) in the blood is a recent area of great interest in CRC screening[<xref rid="B46" ref-type="bibr">46</xref>-<xref rid="B49" ref-type="bibr">49</xref>]. Although these biomarker tests show promising sensitivities, their high costs and high test positivity rates may lead to greater demands on endoscopy departments, and the absence of large-scale validation currently remains the main limitation of their routine use in population-based CRC screening programmes[<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>].</p></sec><sec><title>Prognostic and predictive factors</title><p>Many prognostic factors including many socioeconomic and clinical factors are routinely used to optimize and personalize treatment strategies[<xref rid="B50" ref-type="bibr">50</xref>-<xref rid="B53" ref-type="bibr">53</xref>]. However, pathological factors are currently the most powerful tools that are routinely used to adapt therapeutic strategies, especially for conditioning the administration of non-operative treatments, such as chemotherapy and radiotherapy. The TNM international staging system remains the gold-standard for determining both CRC prognosis and treatment indications[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B54" ref-type="bibr">54</xref>-<xref rid="B56" ref-type="bibr">56</xref>]. Unfortunately, this classification is largely imperfect, which is highlighted by the constant changes it undergoes with the advances in the field of CRC research. Furthermore, it has some limitations. In particular, it is inaccurate for some subgroups of patients whose prognosis and indications for adjuvant treatments remain unclear. Therefore, some other pathological prognostic factors are routinely used, such as the presence of lymphovenous and/or perineural invasion[<xref rid="B57" ref-type="bibr">57</xref>-<xref rid="B60" ref-type="bibr">60</xref>], tumour budding[<xref rid="B61" ref-type="bibr">61</xref>,<xref rid="B62" ref-type="bibr">62</xref>] and tumour differentiation grade[<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B64" ref-type="bibr">64</xref>].</p><p>In addition, studies have shown tumour genomics and cellular alterations can supplement clinicopathological factors. Aneuploidy[<xref rid="B65" ref-type="bibr">65</xref>], tumour-infiltrating lymphocytes[<xref rid="B66" ref-type="bibr">66</xref>,<xref rid="B67" ref-type="bibr">67</xref>], overexpression of the CEA in tumours[<xref rid="B68" ref-type="bibr">68</xref>], allelic loss in DCC, TP53, APC and MCC genes[<xref rid="B69" ref-type="bibr">69</xref>,<xref rid="B70" ref-type="bibr">70</xref>], TP53 gene mutations[<xref rid="B71" ref-type="bibr">71</xref>], expression of CD44 protein[<xref rid="B72" ref-type="bibr">72</xref>], high levels of thymidylate synthetase[<xref rid="B73" ref-type="bibr">73</xref>], and the detection of MSI and both <italic>RAS</italic> and <italic>BRAF</italic> genes mutations all play prominent roles in determining CRC prognosis and in personalizing treatments. They are independent strong prognostic factors[<xref rid="B74" ref-type="bibr">74</xref>-<xref rid="B82" ref-type="bibr">82</xref>] and are also predictive of the response to some widely used chemotherapy regimens, including targeted therapies and immunotherapy[<xref rid="B74" ref-type="bibr">74</xref>,<xref rid="B76" ref-type="bibr">76</xref>,<xref rid="B83" ref-type="bibr">83</xref>-<xref rid="B94" ref-type="bibr">94</xref>].</p><p>Serum prognostic factors [<italic>e.g</italic>., C-reactive protein (CRP), carcinoembryonic antigen (CEA), and cfDNA] can also be very useful tools. Both CRP and serum albumin levels are associated with a worse prognosis but are not routinely used as prognostic factors for CRC[<xref rid="B95" ref-type="bibr">95</xref>-<xref rid="B101" ref-type="bibr">101</xref>]. The CEA level is a well-recognized and routinely used independent prognostic factor for CRC[<xref rid="B102" ref-type="bibr">102</xref>,<xref rid="B103" ref-type="bibr">103</xref>]. Persistently elevated CEA levels after treatment are correlated to both a higher risk of recurrence and decreased survival. Similarly, normal CEA levels after treatment are associated with improved recurrence-free and overall survival[<xref rid="B104" ref-type="bibr">104</xref>]. In addition to CRC screening, investigations evaluating cfDNA have recently gained attention in the field of CRC research. The detection and the quantification of specific gene mutations (<italic>RAS</italic> and <italic>BRAF</italic> genes) or DNA methylation alterations[<xref rid="B105" ref-type="bibr">105</xref>,<xref rid="B106" ref-type="bibr">106</xref>] are correlated with CRC prognosis[<xref rid="B107" ref-type="bibr">107</xref>,<xref rid="B108" ref-type="bibr">108</xref>], independent of the tumour stage. In the future, monitoring of cfDNA levels may guide therapeutic strategies[<xref rid="B109" ref-type="bibr">109</xref>,<xref rid="B110" ref-type="bibr">110</xref>] and improve patient follow-up, allowing the earlier detection of recurrence.</p><p>As we previously mentioned, all these screening strategies and prognostic markers present many limitations. Therefore, there is still a need to develop other effective non-invasive screening and prognostic tools to replace or supplement those currently in use, with the aim of decreasing CRC mortality and optimizing treatment strategies. The study of intestinal microbiota provides new leads to identify powerful biomarkers.</p></sec></sec><sec><title>MICROBIAL SIGNATURES IN CRC</title><sec><title>Functions of intestinal microbiota on gut homeostasis</title><p>The intestinal microbiota and its host have coevolved to establish a symbiotic relationship leading to digestive system homeostasis. Many metabolic, immunological, structural and protection functions that are essential to the health of the host are performed by the intestinal microbiota. Thus, one of the major functions of the gut microbiota is to ferment complex carbohydrates in order to produce a large amount of metabolites (short chain fatty acids (SCFAs), bile acids, choline, essential vitamins, <italic>etc</italic>.), some of which represent energetic and nutrient substrates for intestinal cells[<xref rid="B111" ref-type="bibr">111</xref>,<xref rid="B112" ref-type="bibr">112</xref>]. Others are involved in the regulation of cellular processes or participate in regulating hepatic lipid and glucose homeostasis[<xref rid="B112" ref-type="bibr">112</xref>,<xref rid="B113" ref-type="bibr">113</xref>]. Another function of the gut microbiota is the maintenance of epithelial homeostasis since commensal bacteria can promote epithelial integrity[<xref rid="B114" ref-type="bibr">114</xref>]. They can induce structural and functional maturation of the colonic epithelium with strong modulation of mucus cells[<xref rid="B115" ref-type="bibr">115</xref>]. The intestinal microbiota also plays a fundamental role in the development, maturation and function of the host immune system[<xref rid="B115" ref-type="bibr">115</xref>,<xref rid="B116" ref-type="bibr">116</xref>] and also confers resistance to colonization by pathogenic microorganisms by competing both for nutrients and attachment sites to the intestinal epithelium, by producing and secreting antimicrobial compounds, such as bacteriocins, and by strengthening epithelial tight junctions[<xref rid="B117" ref-type="bibr">117</xref>].</p></sec><sec><title>CRC-associated gut microbiota dysbiosis</title><p><bold>Approaches used to study the gut microbiome:</bold> The gut microbiota has a very large diversity of microbial populations such as bacteria, archaea, eukaryotes and viruses. Because the colonic microbiota is mostly represented by bacteria, the bacterial community is the most studied. Both tissue and faecal samples provide information about the structure of bacterial populations. The analysis of tissues is more relevant for evaluating the mechanisms of microbiota involvement in physiopathology. However, sampling of mucosa-associated bacteria by endoscopic biopsy of intestinal tissue is an invasive procedure. It is more difficult to implement than collection of a faecal sample, especially in healthy donors. Therefore, the vast majority of studies on the diversity and richness of the gut microbiota are conducted on stool samples, which are more useful for identifying diagnostic or prognostic markers for pathologies such as CRC.</p><p>The first data concerning the gut microbiota were provided by cultural approaches. However, these approaches allow only limited evaluation of this ecosystem, since less than 30% of intestinal bacteria have been cultivated to date. Since the 1990s, the advent of molecular tools targeting the bacterial 16S ribosomal RNA (rRNA) gene has revolutionized our knowledge of the gut microbiota from both faeces and tissues. Thus, genetic fingerprinting techniques (terminal restriction fragment length polymorphism (T-RFLP), denaturing gradient gel electrophoresis (DGGE), hybridization approaches (fluorescence in situ hybridization (FISH), microarrays) and clone library analysis have been applied to provide a more complete description of its structure[<xref rid="B118" ref-type="bibr">118</xref>-<xref rid="B122" ref-type="bibr">122</xref>]. Currently, quantitative PCR (Q-PCR) and 16S rRNA gene next-generation sequencing (NGS) are the most used methods for describing the composition of the intestinal bacterial community and therefore for comparing the gut microbiota of healthy individual to that of patients with diseases. Thus, modifications in the microbiota composition, also called dysbiosis, in faeces and tissues have been described in CRC[<xref rid="B123" ref-type="bibr">123</xref>-<xref rid="B130" ref-type="bibr">130</xref>]. These different approaches allow only taxonomic identification of microbial communities. However, the gut is a complex and variable ecosystem. Understanding its function and the specific role of the different bacterial populations is essential. A metagenomics approach (shotgun sequencing) makes taxa identification possible and allows exploration of the metabolic potential of the intestinal microbiota[<xref rid="B126" ref-type="bibr">126</xref>,<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B132" ref-type="bibr">132</xref>]. Thus, the American Human Microbiome Project (HMP) and the European &#x0201c;MetaHIT&#x0201d; (Metagenomics of the Human Intestinal Tract) consortia were formed in order to generate a catalogue of genes carried by the gut microbiota[<xref rid="B133" ref-type="bibr">133</xref>]. Intestinal microbial dysbiosis was recently investigated in patients with CRC[<xref rid="B125" ref-type="bibr">125</xref>,<xref rid="B126" ref-type="bibr">126</xref>,<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B132" ref-type="bibr">132</xref>]. Combining the metagenomics data available in databases with the application of other high-throughput meta-omics approaches, it is now possible to gain a better insight into the microbial function and to reveal the link between genetic potential and functionality in the gut microbiota.</p><p><bold>Cancer-associated microbiome alterations:</bold> To date, there is no consensus in terms of the microbiota modifications observed in CRC using high-throughput sequencing of the bacterial 16S rRNA gene and metagenomics both in faecal and tissue samples compared with samples from healthy individuals. The complexity of the gut microbial ecosystem associated with other technical or biological parameters, such as the geographical location of the studied populations, the lifestyle, the diet, the sample type (faeces, mucosa, tumour), the location of the tissue sampled (<italic>i</italic>.<italic>e</italic>., right or left colon), the age of the individual, the stage of the disease, the number of patients studied, the molecular approach used (metagenomics, 16S rRNA gene NGS), the regions of the 16S rRNA targeted (V1-V2, V3, V3-V5, V4-V6 regions) for the NGS approach, and the taxonomic level considered, contribute to the lack of consensus on the definition of the composition of dysbiotic microbiota in patients with CRC.</p><p>Alpha diversity metrics, which represent the specific richness and the distribution of individuals within the species were found to be increased in adenoma and adenocarcinoma tissues compared with in normal mucosa[<xref rid="B134" ref-type="bibr">134</xref>-<xref rid="B136" ref-type="bibr">136</xref>]. However, these parameters were unchanged in faecal samples[<xref rid="B125" ref-type="bibr">125</xref>,<xref rid="B134" ref-type="bibr">134</xref>,<xref rid="B137" ref-type="bibr">137</xref>,<xref rid="B138" ref-type="bibr">138</xref>], suggesting that the increase in diversity was limited to the neoplastic lesions and did not extend to the entire mucosa.</p><p>Significant shifts can be observed in the composition of the bacterial community at the phylum taxonomic level but also on a finer phylogenetic scale in CRC samples. However, these modifications vary depending on the analytic techniques used and the sample location (mucosa, adenocarcinoma, stool). It is accepted that <italic>Bacteroidetes</italic>, <italic>Fusobacteria</italic> and <italic>Proteobacteria</italic> are enriched, while <italic>Firmicutes</italic> is decreased in CRC patients[<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B139" ref-type="bibr">139</xref>] (Figure <xref ref-type="fig" rid="F1">1</xref>). A similar dysbiosis has been described in CRC animal models[<xref rid="B140" ref-type="bibr">140</xref>,<xref rid="B141" ref-type="bibr">141</xref>]. In a taxonomy-based analyses conducted in 2013, Ahn et al[<xref rid="B142" ref-type="bibr">142</xref>] described a lower relative abundance of <italic>Clostridia</italic> and increased <italic>Fusobacterium</italic> and <italic>Porphyromonas</italic> in case subjects compared with control subjects. Additionally, the genera <italic>Bacteroides</italic> and <italic>Prevotella</italic>, <italic>Bacteroides fragilis</italic>, <italic>Enterococcus faecalis</italic>, <italic>Streptococcus bovis, Streptococcus gallolyticus</italic> and <italic>Escherichia coli</italic> were overrepresented, while <italic>Bacteroides vulgatus, Lactobacillus</italic> and <italic>Faecalibacterium prausnitzii</italic> were decreased in the faeces or tumours of patients with CRC[<xref rid="B123" ref-type="bibr">123</xref>-<xref rid="B125" ref-type="bibr">125</xref>,<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B143" ref-type="bibr">143</xref>-<xref rid="B146" ref-type="bibr">146</xref>]. Other studies found that <italic>Parvimonas micra</italic>, <italic>Solobacterium moorei</italic>, <italic>Peptostreptococcus stomatis</italic> were consistently enriched in the microbiomes of the stools of CRC patients[<xref rid="B126" ref-type="bibr">126</xref>,<xref rid="B131" ref-type="bibr">131</xref>]. Many studies showed an enrichment of <italic>Fusobacterium nucleatum</italic> in stool and tissue samples from patients with colorectal carcinoma, which were confirmed by quantitative polymerase chain reaction (PCR)[<xref rid="B126" ref-type="bibr">126</xref>,<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B147" ref-type="bibr">147</xref>-<xref rid="B149" ref-type="bibr">149</xref>] (Figure <xref ref-type="fig" rid="F1">1</xref>). In addition to taxonomic studies, a metagenomics analysis showed an enrichment of virulence-associated bacterial genes in the tumour microenvironment[<xref rid="B132" ref-type="bibr">132</xref>]. Many studies reported a high prevalence of toxin genes expressed by some species described above. Most of enterotoxigenic <italic>B. fragilis</italic> (ETBF) strains detected in mucosal samples from patients with CRC harboured the <italic>bft</italic> gene, which encodes the bacterial toxin <italic>B. fragilis</italic> toxin (BFT)[<xref rid="B149" ref-type="bibr">149</xref>] (Figure <xref ref-type="fig" rid="F1">1</xref>). ETBF and BFT carrying strains were detected more often in stool samples from CRC patients compared with samples from controls[<xref rid="B150" ref-type="bibr">150</xref>]. Many studies reported that mucosa-associated BFT-producing <italic>B. fragilis</italic> was more prevalent in late-stage CRC[<xref rid="B130" ref-type="bibr">130</xref>,<xref rid="B149" ref-type="bibr">149</xref>]. Other toxins named cyclomodulins [cytolethal distending toxin (CDT), colibactin, cytotoxic necrotizing factor and cycle inhibiting factor], which are carried by <italic>E. coli</italic>, were more prevalent in CRC samples[<xref rid="B145" ref-type="bibr">145</xref>,<xref rid="B146" ref-type="bibr">146</xref>,<xref rid="B151" ref-type="bibr">151</xref>,<xref rid="B152" ref-type="bibr">152</xref>]. In particular, the colibactin toxin, which is synthesised from the <italic>pks</italic> island, was preferentially detected in strains isolated from CRC patients[<xref rid="B145" ref-type="bibr">145</xref>,<xref rid="B146" ref-type="bibr">146</xref>,<xref rid="B152" ref-type="bibr">152</xref>] (Figure <xref ref-type="fig" rid="F1">1</xref>). These toxin genes could be targets of interest for developing new prognostic or diagnostic factors.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Bacterial and metabolic composition shifts during carcinogenesis. BFT: <italic>B</italic>. <italic>fragilis</italic> toxin.</p></caption><graphic xlink:href="WJG-24-2327-g001"/></fig><p>The majority of published data were obtained in the adenocarcinoma stage. However, the intestinal mucosa might present different ecological niches according to the stage of colorectal tumour progression. Due to difficulties in sampling patients during the early stages of the disease, studies focusing on the temporal evolution of microbiota dysbiosis during colorectal carcinogenesis are scarce. Nevertheless, metacommunities can be defined from the bacterial community configurations by Nakatsu et al[<xref rid="B153" ref-type="bibr">153</xref>]. In early stages of CRC, bacteria belonging to <italic>Fusobacterium</italic>, <italic>Parvimonas</italic>, <italic>Gemella</italic> and <italic>Leptotrichia</italic> genera were more abundant[<xref rid="B153" ref-type="bibr">153</xref>]. Moreover, the occurrence of <italic>Escherichia coli, Pseudomonas veronii</italic> and <italic>Lactococcus</italic> were specific to adenomatous lesions[<xref rid="B135" ref-type="bibr">135</xref>,<xref rid="B153" ref-type="bibr">153</xref>], whereas <italic>Fusobacterium</italic> enrichment was observed in carcinomas[<xref rid="B153" ref-type="bibr">153</xref>]. Additionally, the abundance of <italic>Bacteroides fragilis</italic> and <italic>Granulicatella</italic> were progressively increased during the adenoma-carcinoma sequence. Lu et al[<xref rid="B135" ref-type="bibr">135</xref>] showed that there was a clear increase in both <italic>Proteobacteria</italic> and <italic>Bacteroidetes</italic> in tissues from patients with colorectal adenoma compared with tissues from healthy volunteers. Kostic et al[<xref rid="B147" ref-type="bibr">147</xref>] found that <italic>Fusobacterium</italic> spp. were enriched in human colonic adenomas relative to the surrounding tissues and in stool samples from patients with colorectal adenoma compared with samples from healthy subjects. In addition, <italic>Lactococcus</italic> and <italic>Pseudomonas</italic> were enriched in preneoplastic tissue, whereas <italic>Enterococcus</italic>, <italic>Bacillus</italic>, and <italic>Solibacillus</italic> were reduced. A high frequency of colibactin-producing <italic>E. coli</italic> and enterotoxigenic <italic>Bacteroides fragilis</italic> were also observed in adenomas from patients with Familial Adenomatous Polyposis[<xref rid="B154" ref-type="bibr">154</xref>]. Recently, Ekl&#x000f6;f et al[<xref rid="B151" ref-type="bibr">151</xref>] showed that the prevalence of colibactin-producing <italic>E. coli</italic> were progressively increased in the adenoma-carcinoma sequence.</p><p>Finally, most of these studies do not take into account the heterogeneity of this pathology. As an example, <italic>Prevotella</italic> and <italic>Firmicutes</italic> populations were more abundant in individuals with proximal tumours, whereas <italic>Bacteroidetes</italic> populations were overrepresented in distal cancers[<xref rid="B155" ref-type="bibr">155</xref>]. More recently, a drastic difference in the microbial composition has been observed in the mucosa of colitis-associated CRC patients, with an increase in the <italic>Enterobacteriaceae</italic> family and the <italic>Sphingomonas</italic> genus and a decrease in <italic>Fusobacterium</italic> and <italic>Ruminococcus</italic> genera, when compared with the mucosa of sporadic CRC patients[<xref rid="B156" ref-type="bibr">156</xref>]. Similarly, we observed that colibactin-producing <italic>E. coli</italic> were more frequently identified in microsatellite stable (MSS) CRC[<xref rid="B157" ref-type="bibr">157</xref>]. In the same way, high colonization by <italic>F. nucleatum</italic> and negative-colibactin <italic>E. coli</italic> bacteria were detected in patients with MSI (microsatellite instability) compared with the MSS phenotype[<xref rid="B149" ref-type="bibr">149</xref>,<xref rid="B157" ref-type="bibr">157</xref>,<xref rid="B158" ref-type="bibr">158</xref>]. All these data suggest that the dysbiosis signature of CRC might be different according to the tumour phenotype and/or molecular alterations.</p><p>In conclusion, all these data show that there is an adenoma- and a CRC-associated signature in the microbiome (Figure <xref ref-type="fig" rid="F1">1</xref>). Metagenomics studies showed a redundancy in the metabolic functions of the intestinal microbiota. Therefore, studies of metabolites might reflect the CRC-associated microbiota dysbiosis with a lower heterogeneity than taxonomic determination.</p></sec><sec><title>Profiling metabolome alterations in CRC</title><p><bold>Metabolite analysis procedures:</bold> The metabolome has been defined as the complete complement of all small molecule (&#x0003c; 1500 Da) metabolites found in a specific cell, organ or organism[<xref rid="B159" ref-type="bibr">159</xref>]. Global metabolomics alterations reflect changes due to environmental factors, diet, drugs, exercise, genetic variation and regulation, changes in the gut microflora, and altered kinetic activity or levels of enzymes[<xref rid="B160" ref-type="bibr">160</xref>]. The most widely used analytical high-throughput tools for metabolomics studies are nuclear magnetic resonance (NMR) and mass spectrometry (MS), and they both can provide complementary snapshots of the metabolome of body fluids[<xref rid="B161" ref-type="bibr">161</xref>]. Sample preparation is arguably the most critical step in metabolomics, but there is no universal, robust and repeatable approach defined. NMR spectroscopy benefits from being highly reproducible[<xref rid="B162" ref-type="bibr">162</xref>] and offers the potential to precisely quantify compounds in complex mixtures without complex sample preparation requirements[<xref rid="B163" ref-type="bibr">163</xref>]. Gas chromatography coupled with MS (GC-MS), which is used for the analysis of volatile low molecular weight metabolites, and liquid chromatography coupled with MS (LC-MS), which is used for the analysis of non-volatile components, have a higher sensitivity than NMR, but the sample preparation must be more fastidious. For more details regarding sample preparation in metabolomics, several authors previously described methods for NMR, GC-MS and LC-MS analysis[<xref rid="B163" ref-type="bibr">163</xref>].</p><p>During the last decade, using NMR and/or MS, metabolic profiles of colorectal tumour biopsies and matched colon mucosa samples revealed potential biomarkers in carbohydrate metabolism, short-chain fatty acid and other lipid metabolism, nucleotide biosynthesis, and secondary bile and steroid metabolism[<xref rid="B164" ref-type="bibr">164</xref>,<xref rid="B165" ref-type="bibr">165</xref>]. The repertoire of metabolic derangements derived from cancer cells, their microenvironment and the gut microbiota composition and activity may culminate in a distinct metabolic phenotype (also called metabotype) that characterizes the pathology of CRC. Metabolome analysis of blood and urine samples from CRC patients were performed, and several studies reported relevant biomarkers for CRC[<xref rid="B166" ref-type="bibr">166</xref>-<xref rid="B168" ref-type="bibr">168</xref>]. However, the transient localization of faeces in the colon and rectum makes it an ideal matrix for gaining information about the health and pathological state of the colon and rectum, and thus for colorectal cancer diagnosis[<xref rid="B169" ref-type="bibr">169</xref>]. Faecal samples consist of a diverse range of endogenous metabolites including tumour cell metabolites and gut microbiota metabolites[<xref rid="B169" ref-type="bibr">169</xref>].</p><p><bold>Microbial influence on the faecal metabolome:</bold> When ingested, the majority of food nutrients are absorbed in the small intestine. The residues that reach the colon are complex nutrients, generally fibres (complex carbohydrates), but also protein residues and host products such as mucin and bile acids secreted by the liver in response to fat ingestion[<xref rid="B170" ref-type="bibr">170</xref>]. These compounds are metabolized by the microbial populations into a diversity of metabolites that can be use by the host colonic cells[<xref rid="B171" ref-type="bibr">171</xref>]. The gut microbiota makes an important contribution to human metabolism by providing enzymatic functions that are not encoded by the human genome, such as the breakdown of polysaccharides and polyphenols and the synthesis of vitamins by fermentation and anaerobic degradation[<xref rid="B172" ref-type="bibr">172</xref>].</p><p>Polysaccharides and non-digestible carbohydrates are the primary substrates for microbial fermentation[<xref rid="B173" ref-type="bibr">173</xref>]. Saccharolytic fermentation of carbohydrates produces beneficial metabolites such as short-chain fatty acids[<xref rid="B174" ref-type="bibr">174</xref>]. However, if there is limited carbohydrate intake, bacteria use alternative energy sources, resulting in the production of other metabolites that may be more detrimental to human health[<xref rid="B172" ref-type="bibr">172</xref>]. The three SCFAs acetate, propionate and butyrate, which are considered beneficial metabolites, are mainly produced from polysaccharides and oligosaccharides through their metabolism into pyruvate (Figure <xref ref-type="fig" rid="F2">2</xref>). Propionate and acetate can be produced from lactate, while butyrate and acetate can be produced from acetyl CoA (Figure <xref ref-type="fig" rid="F2">2</xref>)[<xref rid="B171" ref-type="bibr">171</xref>]. Butyrate is an important energy source for gut epithelial cells, while propionate and acetate are mostly metabolized in the liver for cholesterol synthesis, gluconeogenesis or lipogenesis[<xref rid="B175" ref-type="bibr">175</xref>]. For more information, the complete synthesis and functions of SCFAs was extensively and previously described[<xref rid="B113" ref-type="bibr">113</xref>,<xref rid="B175" ref-type="bibr">175</xref>]. Microbial use of bile salts is a classic example of the relationship between the gut microbiota metabolism and the host metabolism. The primary bile acids cholic acid and chenodeoxycholic acid are produced in the liver from cholesterol and are conjugated to glycine or taurine. They are secreted by the liver following high fat intakes[<xref rid="B176" ref-type="bibr">176</xref>]. The intestinal microbiota can affect the biotransformation of bile acids <italic>via</italic> deconjugation, dehydrogenation, epimerization, and 7&#x003b1;/&#x003b2;-dehydroxylation of primary bile acids to generate secondary bile acids[<xref rid="B177" ref-type="bibr">177</xref>]. A number of gut bacteria possess bile salt hydrolase enzymes that are capable of hydrolysing the amide bond between the bile acid and its conjugated amino acid, producing the secondary bile acids deoxycholate and litocholate (Figure <xref ref-type="fig" rid="F2">2</xref>). Bile salt hydrolase genes were identified in <italic>Bacteroides</italic>, <italic>Bifidobacterium</italic>, <italic>Clostridium</italic>, <italic>Lactobacillus</italic>, and <italic>Listeria</italic>[<xref rid="B178" ref-type="bibr">178</xref>]. Deconjugation of bile acids by microbial hydrolases leads to an increased level of secondary bile acids, especially deoxycholic acid, which is also known to exert carcinogenic activity[<xref rid="B179" ref-type="bibr">179</xref>]. Polyphenols from fruits and vegetables are poorly absorbed in the intestine, and 90-95% are metabolized by the gut microbiota[<xref rid="B180" ref-type="bibr">180</xref>]. The diversity of polyphenol compounds is wide and has been summarized by Mar&#x000ed;n et al[<xref rid="B181" ref-type="bibr">181</xref>] and Rowland et al[<xref rid="B172" ref-type="bibr">172</xref>]. Several gut microbial enzymes can transform plant polyphenols, such as phenolic acids, flavonoids, and lignans into simple phenolic metabolites[<xref rid="B172" ref-type="bibr">172</xref>,<xref rid="B181" ref-type="bibr">181</xref>,<xref rid="B182" ref-type="bibr">182</xref>]. These microbial phenolic metabolites are mostly known for their antioxidant activity and have been shown to inhibit the production of pro-inflammatory mediators[<xref rid="B183" ref-type="bibr">183</xref>]. Microbial protein fermentation generates potentially toxic and pro-carcinogenic metabolites involved in CRC, such as phenols, sulfides, ammonia and nitrosamines[<xref rid="B7" ref-type="bibr">7</xref>]. A subset of bacteria, including <italic>Bacteroidetes</italic> and <italic>Firmicutes</italic> species, produce potentially bioactive substances <italic>via</italic> the degradation of amino acids, especially nitrogenous compounds that can exert carcinogenic effects[<xref rid="B184" ref-type="bibr">184</xref>-<xref rid="B186" ref-type="bibr">186</xref>]. Moreover, sulfides produced in the gut by the bacterial reduction of dietary sulfate are enterotoxic[<xref rid="B187" ref-type="bibr">187</xref>]. Microbial metabolism may contribute to the toxicity of alcohol, especially in the gastrointestinal tract where aerobic and facultative anaerobic bacteria convert ethanol to acetaldehyde, which is known to be a highly toxic and pro-carcinogenic compound[<xref rid="B188" ref-type="bibr">188</xref>]. A specific role for bacterial biofilms in colonic metabolome was also reported[<xref rid="B189" ref-type="bibr">189</xref>]. With organic acids, gas is the major products of microbial fermentation in anaerobic systems. Anaerobic bacterial fermentation can lead to the synthesis of hydrogen, carbon dioxide, or methane for the majority. Some minor gases, such as NH<sub>3</sub>, NH<sub>2</sub>, volatile amines, indolic and phenolic compounds , that are mainly associated with peptide fermentation, are also produced[<xref rid="B190" ref-type="bibr">190</xref>,<xref rid="B191" ref-type="bibr">191</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>). Among them, H<sub>2</sub>S is produced by sulfate-reducing bacteria (<italic>Desulfovibrio</italic> spp.) by sulfur amino acids and taurine metabolism.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Metabolism of food dietary components by the gut microbiota. Dietary residues are in blue, intermediate metabolites in green, SCFAs in red, and other metabolites in grey. Adapted from Louis et al[<xref rid="B255" ref-type="bibr">255</xref>], Russel et al[<xref rid="B184" ref-type="bibr">184</xref>] ; Rowland et al[<xref rid="B172" ref-type="bibr">172</xref>] ; Flint et al[<xref rid="B171" ref-type="bibr">171</xref>]. SCFAs: Short chain fatty acids.</p></caption><graphic xlink:href="WJG-24-2327-g002"/></fig><p>Given the key role of the gut microbiota in dietary metabolism and the growing evidence of its potential impact on host health, studies were performed to elucidate the metabolic functions of the gut microbiota. These studies mostly used metagenomic, metatranscriptomic, or metaproteomic approaches, but using metabolomics to study the gut microbiota appears to be a promising method. Indeed, metabolomics allow the measurement of both host and microbial metabolites, including metabolites in host samples derived from the microbiota and host metabolites processed by the microbial population.</p><p><bold>Metabolome alterations in CRC:</bold> The analysis of the CRC-associated metabolome has highlighted differences in the biochemical composition of CRC patients&#x02019; stools. Few animal studies have investigated the metabolomic profile of faeces in CRC models. Significant alterations were observed in fatty acid metabolites and metabolites associated with bile acids (hypoxanthine xanthine, taurine) in faeces of <italic>Hmga1</italic> mice as analysed by ultra-performance liquid chromatography UPLC/MS/MS and GC-MS[<xref rid="B192" ref-type="bibr">192</xref>]. Increased levels of short, arginine-enriched, tetra-peptide fragments were reported in the transgenic mouse faeces[<xref rid="B192" ref-type="bibr">192</xref>]. Similarly, CRC patients were found to have higher levels of some amino acids and alterations in the levels of some SCFA in their stools compared with controls[<xref rid="B193" ref-type="bibr">193</xref>]. Butyrate and several butyrate-producing bacteria were depleted in CRC patients&#x02019; stools[<xref rid="B194" ref-type="bibr">194</xref>]. Chen et al[<xref rid="B143" ref-type="bibr">143</xref>] observed that butyrate and butyrate-producing bacteria were more prevalent in healthy controls than in advanced colorectal adenoma patients, with a lower prevalence of <italic>Clostridium</italic>, <italic>Roseburia</italic>, and <italic>Eubacterium</italic> spp. and a higher prevalence of <italic>Enterococcus</italic> and <italic>Streptococcus</italic> spp. Moreover, faecal &#x003b2;-glucuronidase activity is increased in patients with CRC compared with healthy controls[<xref rid="B195" ref-type="bibr">195</xref>]. High-fat diets, which are positively correlated with the incidence of CRC, lead to an increase in bile secretion, and increased faecal bile acid concentrations were reported in patients with CRC[<xref rid="B196" ref-type="bibr">196</xref>]. High faecal bile concentrations were positively correlated with the incidence of CRC, with potential tumour-promoting effects of bile acids themselves[<xref rid="B176" ref-type="bibr">176</xref>]. Furthermore, strong antimicrobial bile acid activities lead to significant changes in the gut microbiota composition, with a relative increase in some <italic>Gammaproteobacteria</italic> and <italic>Bacteroidetes</italic> species that are associated with CRC[<xref rid="B197" ref-type="bibr">197</xref>]. The dietary intake of preformed N-nitroso compounds is positively correlated with CRC in European populations[<xref rid="B185" ref-type="bibr">185</xref>], but these compounds can also be formed endogenously <italic>via</italic> acid-driven nitrosation in the stomach and by the nitrosation of amines that are derived from the microbial fermentation of protein in the large intestine[<xref rid="B198" ref-type="bibr">198</xref>]. Higher levels of H<sub>2</sub>S were detected in CRC patients than those in healthy controls, but no increases in <italic>Desulfovibrio</italic> spp. were observed in faecal samples from patients with CRC[<xref rid="B199" ref-type="bibr">199</xref>]. Using metabolome screening, a metabolic influence of microbial biofilms on colonic tissues and the related occurrence of cancer has been reported. It was found that host cancer and specific bacterial biofilm structures contributed to the polyamine metabolite pool (N<sup>1</sup>,N<sup>12</sup>-diacetylspermine), which might have an impact on cancer development and progression[<xref rid="B189" ref-type="bibr">189</xref>].</p><p>All these data suggest that faecal metabolomics may not only be used for diagnostic purposes but may also serve as a prognostic tool for CRC treatment in the future.</p></sec></sec><sec><title>MICROBIAL-RELATED BIOMARKERS FOR CRC DIAGNOSIS AND CLASSIFICATION</title><sec><title>Validation of multi-bacteria models for early detection and/or prognosis determination</title><p>Even if a precise microbial signature associated with CRC and a precancerous lesion have not been exactly defined, different works have shown that dysbiosis may provide new significant biomarkers for CRC diagnosis or prognostic determination.</p><p>Several studies were able to determine a correlation between faecal microbial dysbiosis and CRC prognosis/diagnosis. In 2014, Zackular et al[<xref rid="B140" ref-type="bibr">140</xref>] used faecal samples from 30 CRC patients, 30 colonic adenoma patients and 30 healthy controls to establish a classification model. The authors observed significant differences in the gut microbiome of healthy controls when compared with those with adenoma or CRC, and faecal microbial screening had an accuracy of 0.798 AUC for predicting CRC. By combining their gut microbiome data with known clinical risk factors (body mass index, age, race), they were able to significantly improve the ability of faecal microbial screening to discriminate between the three clinical groups when compared with risk factors alone. Zeller et al[<xref rid="B131" ref-type="bibr">131</xref>], with 53 CRC patients, 42 adenoma patients and 61 controls, established a 16S-based classifier for CRC detection and validated their model with an accuracy of 0.82. More recently, Ai et al[<xref rid="B200" ref-type="bibr">200</xref>] sequenced the 16S rRNA gene from the faeces of 141 Chinese participants and evaluated the performance of different classifiers for predicting CRC based on faecal microbiota. The authors reported a strong variation in the CRC prediction between the different models tested, with the Bayes Net algorithm displaying the best performance. Their prediction test, with 0.93 AUC, was more accurate than the FOBT, while combining both tests improved the accuracy. This list of studies that assessed the use of changes in the faecal microbiota for colorectal adenoma and CRC screening is non-exhaustive. Among these studies, while an association between CRC and microbiota is clear, there is limited agreement in the taxa reported.</p><p>For this reason, Shah et al[<xref rid="B201" ref-type="bibr">201</xref>] conducted a microbiome-based meta-analysis for CRC, using the results from 9 studies and including 79 colorectal adenomas patients, 195 CRC patients and 235 controls, in order to identify a common microbial marker in stool samples. In addition to the previously reported taxa, they highlighted a significant increase in <italic>Parvimonas micra</italic> ATCC 33270, <italic>Streptococcus anginosus</italic>, <italic>Parabacteroides distasonis</italic> and other members of <italic>Proteobacteria</italic>. Their microbiome-based CRC versus control classification produced an area under the receiver operating characteristic (AUROC) curve of 80.3%, which was 91.3% when combined with clinical markers from the bioinformatics pipeline. Similarly, Amitay et al[<xref rid="B202" ref-type="bibr">202</xref>] conducted a systematic review of 19 studies (including most of the studies cited above) examining the differences in the gut microbial community in faecal samples from people diagnosed with CRC or adenomas and from people without colorectal neoplasia to generate faecal multi-bacterial models for early detection of adenomas and CRC. Overall, they concluded that there was limited but encouraging evidence that the differences in the faecal gut microbiome between people diagnosed with CRC or adenoma and healthy controls could be used to develop new faecal tests. The authors suggested that future research should focus on developing unified documented and reproducible protocols for studying the human gut microbiome from faecal samples for more comparable results between cohorts[<xref rid="B202" ref-type="bibr">202</xref>].</p><p>In many studies, patients had a corresponding decrease in the <italic>Firmicutes/Bacteroidetes</italic> ratio, which might be an important marker for intestinal dysbiosis in colorectal precancerous lesions. <italic>F. nucleatum</italic>, BFT-producing <italic>B. fragilis</italic>, and colibactin-producing <italic>E. coli</italic> are known to be associated with a more aggressive TNM stage[<xref rid="B130" ref-type="bibr">130</xref>,<xref rid="B145" ref-type="bibr">145</xref>,<xref rid="B149" ref-type="bibr">149</xref>,<xref rid="B158" ref-type="bibr">158</xref>]. Their detection by PCR in tissues or faeces might allow the development of rapid tests for new prognostic factors. With a 16S rRNA gene sequencing approach, <italic>F. nucleatum</italic>, <italic>B. fragilis</italic> and <italic>Faecalibacterium prausnitzii</italic> were identified as useful prognostic biomarkers for CRC[<xref rid="B203" ref-type="bibr">203</xref>]. Indeed, in this study, <italic>F. nucleatum</italic> and <italic>B. fragilis</italic> were more abundant in the groups with a worse prognosis, while <italic>Faecalibacterium prausnitzii</italic> was more abundant in the survival group. Similarly, Mima et al[<xref rid="B158" ref-type="bibr">158</xref>] showed that the amount of <italic>F. nucleatum</italic> DNA in colorectal cancer tissue was associated with shorter survival. Another study demonstrated that the detection of <italic>F. nucleatum</italic> associated with the non-invasive screening FIT could be a promising marker for detecting neoplastic lesions[<xref rid="B204" ref-type="bibr">204</xref>]. Recently, Ekl&#x000f6;f et al[<xref rid="B151" ref-type="bibr">151</xref>] explored the use of microbial markers for bacteria harbouring the pks island, which codes for colibactin synthesis, and <italic>F. nucleatum</italic> in stool as potential screening markers for CRC. Authors suggested that the presence of the pks island and <italic>F. nucleatum</italic> detection could predict cancer with a specificity of 63.1% and a sensitivity of 84.6%, suggesting the potential value of these microbial parameters as putative non-invasive biomarkers for CRC detection[<xref rid="B151" ref-type="bibr">151</xref>]. Multicentric clinical studies need to be performed to validate all these promising results in a larger cohort. Moreover, these bacterial markers might provide a CRC-associated microbiome risk profile that might aid in the early identification of individuals who are at risk and require close surveillance.</p></sec><sec><title>Screening faecal microbial-related metabolites for CRC detection</title><p>Screening the faecal metabolome is a promising non-invasive procedure for obtaining a unique metabolic fingerprint to diagnose or determine the prognosis of CRC. To our knowledge, only a few studies with different metabolomics methods have shown the diagnostic potential of faecal samples for human colorectal cancer. They are summarized in Table <xref ref-type="table" rid="T1">1</xref>. In 2009, Bezabeh et al[<xref rid="B205" ref-type="bibr">205</xref>] used <sup>1</sup>H NMR to detect colorectal neoplasia in 111 CRC human faecal samples and compared them with samples from 412 healthy controls. NMR-based metabolic profiling of faecal water extracts from patients with colorectal cancer and healthy individuals was able to identify potential diagnostic markers, such as SCFA (acetate and butyrate) and amino acids (proline and cysteine)[<xref rid="B206" ref-type="bibr">206</xref>]. More recently, the analysis of lyophilized stools by HPLC-GC/MS-MS resulted in the identification of 41 relevant faecal metabolites, such as xenobiotics, heme, peptides/amino acids, vitamins and co-factors, that had increased or decreased concentrations in CRC samples[<xref rid="B207" ref-type="bibr">207</xref>]. Volatile metabolome profiling of faecal samples using GC/TOF-MS also had diagnostic potential for detecting colorectal cancer. Phua et al[<xref rid="B208" ref-type="bibr">208</xref>] evaluated a small cohort and identified three specific markers (fructose, linoleic acid, and nicotinic acid) that were found at lower levels in the faecal volatile metabolome of CRC patients than in that of healthy subjects. A similar study using an electronic nose on samples from 40 CRC patients, 60 advanced adenoma patients, and 57 healthy controls was able to strongly distinguish the faecal volatile organic compounds (VOC) profile of patients with CRC and advanced adenoma from controls[<xref rid="B209" ref-type="bibr">209</xref>]. Given the volatility of the analysed compounds, improper sample collection and storage can drastically reduce the repeatability and robustness of the method. Batty et al[<xref rid="B210" ref-type="bibr">210</xref>] proposed the use of selected ion flow tube mass spectrometry (SIFT-MS) to classify 62 human faecal samples with a positive result on FOBT. Indeed, their method showed a 75% correct discrimination between CRC samples and low risk samples[<xref rid="B210" ref-type="bibr">210</xref>]. More recently, Sinha et al[<xref rid="B211" ref-type="bibr">211</xref>] intended to establish a microbe-metabolite correlation through the analysis of lyophilized faecal samples of 42 CRC patients and 89 healthy controls using HPLC-GC/MS-MS. They reported that CRC was independently associated with lower levels of <italic>Clostridia</italic>, <italic>Lachnospiraceae</italic>, <italic>p</italic>-aminobenzoate and conjugated linoleate and with higher levels of <italic>Fusobacterium</italic>, <italic>Porphyromonas</italic>, p-hydroxy-benzaldehyde, and palmitoyl-sphingomyelin. The authors identified a strong microbe-metabolite correlation in CRC patients. In conclusion, the diagnostic potential of metabolic profiling of faeces is strongly supported by several human studies, but these analytical techniques require standard procedures in order to obtain comparable and robust high-quality data.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Fecal metabolic profiling studies in colorectal cancer</p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><bold>Matrix</bold></td><td rowspan="1" colspan="1"><bold>Cohort</bold></td><td rowspan="1" colspan="1"><bold>Study observations</bold></td><td rowspan="1" colspan="1"><bold>Analytical method</bold></td><td rowspan="1" colspan="1"><bold>Ref</bold>.</td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1">Aqueous dispersion of stools</td><td rowspan="1" colspan="1">111 CRC, 412 healthy controls</td><td rowspan="1" colspan="1">Potential to detect colorectal neoplasia</td><td rowspan="1" colspan="1">One-dimensional <sup>1</sup>H magnetic resonance spectroscopy</td><td rowspan="1" colspan="1">[205]</td></tr><tr><td align="left" rowspan="1" colspan="1">Fecal water extract</td><td rowspan="1" colspan="1">21 CRC 11 healthy controls</td><td rowspan="1" colspan="1">Reproducible and effective method for detecting colorectal cancer markers. (&#x02198;) SCFA (acetate, butyrate) appears to be the most effective marker in CRC.</td><td rowspan="1" colspan="1">NMR</td><td rowspan="1" colspan="1">[206]</td></tr><tr><td align="left" rowspan="1" colspan="1">Lyophilized human faeces</td><td rowspan="1" colspan="1">11 CRC 10 healthy controls</td><td rowspan="1" colspan="1">(&#x02198;) butyric acid, linoleic acid, glycerol, (&#x02198;) secondary bile acid associated with (&#x02198;) <italic>Ruminococcus</italic> spp., (&#x02197;) leucine, valine, acetic acid, valeric acid, isobutyric acid, isovaleric acid, (&#x02197;) A. <italic>muciniphila</italic> associated with (&#x02197;) proline, serine, threonine</td><td rowspan="1" colspan="1">GC-MS</td><td rowspan="1" colspan="1">[193]</td></tr><tr><td align="left" rowspan="1" colspan="1">Lyophilized human faeces</td><td rowspan="1" colspan="1">11 CRC, 10 healthy controls</td><td rowspan="1" colspan="1">(&#x02198;) fructose, linoleic acid, and nicotinic acid in CRC stools.</td><td rowspan="1" colspan="1">GC/TOF-MS</td><td rowspan="1" colspan="1">[208]</td></tr><tr><td align="left" rowspan="1" colspan="1">Volatile organic compounds in the headspace of lyophilized stool samples</td><td rowspan="1" colspan="1">40 CRC, 60 advanced adenomas, 57 healthy controls</td><td rowspan="1" colspan="1">Discrimination of fecal VOC profiles of patients with adenomas and CRC.</td><td rowspan="1" colspan="1">Electronic nose</td><td rowspan="1" colspan="1">[209]</td></tr><tr><td align="left" rowspan="1" colspan="1">Lyophilized human faeces</td><td rowspan="1" colspan="1">48 CRC, 102 healthy controls</td><td rowspan="1" colspan="1">41 metabolites significantly associated with CRC (&#x02198;) xenobiotics (&#x02198;) heme, peptides/amino acids, vitamins, co-factors, other CRC associated molecules.</td><td rowspan="1" colspan="1">HPLC-GC/MS-MS</td><td rowspan="1" colspan="1">[207]</td></tr><tr><td align="left" rowspan="1" colspan="1">Human faeces</td><td rowspan="1" colspan="1">31 CRC, 31 controls with positive FOBT</td><td rowspan="1" colspan="1">Discrimination of CRC samples with better specificity and sensitivity than FOBT. (&#x02198;) ammonia, sulfides, acetaldehyde</td><td rowspan="1" colspan="1">SIFT-MS</td><td rowspan="1" colspan="1">[210]</td></tr><tr><td align="left" rowspan="1" colspan="1">Lyophilized human faeces</td><td rowspan="1" colspan="1">42 CRC, 89 healthy controls</td><td rowspan="1" colspan="1">Microbe-metabolite correlation in CRC: (&#x02197;) <italic>Clostridia</italic>, <italic>Lachnospiraceae</italic>, <italic>p</italic>-aminobenzoate and conjugated linoleate. (&#x02197;) <italic>Fusobacterium</italic>, <italic>Porphyromonas</italic>, <italic>p</italic>-hydroxy-benzaldehyde, and palmitoyl-sphingomyelin.</td><td rowspan="1" colspan="1">HPLC-GC/MS-MS</td><td rowspan="1" colspan="1">[211]</td></tr><tr><td align="left" rowspan="1" colspan="1">Human faeces</td><td rowspan="1" colspan="1">13 CRC</td><td rowspan="1" colspan="1">Discrimination of CRC samples with 7 metabolites: alphahydroxyisovalerate, isovalerate, N1-methyl-2-pyridine-5-carboxamide, 7-ketodeoxycholate, deoxycholate, valerate, and tryptophylglycine</td><td rowspan="1" colspan="1">UPLC-MS/MS; GC/MS</td><td rowspan="1" colspan="1">[165]</td></tr></tbody></table><table-wrap-foot><fn><p>CRC: Colorectal cancer; CT: Computed tomography; gFOBT: Guaiac fecal occult blood test; NMR: Nuclear magnetic resonance; MS: Mass spectrometry; GC-MS: Gas chromatography coupled with MS; LC-MS: Liquid chromatography coupled with MS; UPLC: Ultra-performance liquid chromatography; HPLC: High-performance liquid chromatography; TOF: Time of flight; VOC: Volatile organic compounds; SIFT-MS: Selected ion flow tube MS.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Prediction of treatment response with microbial-associated markers</title><p>It has long been recognized that the gut microbiota can modify the pharmacokinetics of various drugs including anticancer therapies thus influencing therapeutic outcomes[<xref rid="B212" ref-type="bibr">212</xref>-<xref rid="B217" ref-type="bibr">217</xref>] and/or side effects[<xref rid="B218" ref-type="bibr">218</xref>-<xref rid="B220" ref-type="bibr">220</xref>]. Irinotecan, which is a first-line chemotherapeutic agent for metastatic CRC, causes adverse and dose-limiting effects that are largely influenced by bacterial &#x003b2;-glucuronidase[<xref rid="B214" ref-type="bibr">214</xref>,<xref rid="B219" ref-type="bibr">219</xref>]. Metagenomic and metabolomic profiling of patients&#x02019; gut microbiota could thus be informative before choosing this drug to predict side effects. Moreover, specific members of the gut microbiota might also drive chemoresistance to treatment. Indeed, <italic>Fusobacterium nucleatum</italic>, causes resistance to oxaliplatin and 5-FU through autophagy induction in colorectal cancer cell lines <italic>in vitro</italic> and <italic>in vivo</italic> in mouse models of colorectal xenografts[<xref rid="B221" ref-type="bibr">221</xref>]. Conversely, the sensitivity of cancer cells to many chemotherapeutic agents has been shown to be modulated by intra-tumoural microbial agents[<xref rid="B212" ref-type="bibr">212</xref>,<xref rid="B215" ref-type="bibr">215</xref>,<xref rid="B216" ref-type="bibr">216</xref>,<xref rid="B221" ref-type="bibr">221</xref>,<xref rid="B222" ref-type="bibr">222</xref>]. Moreover, the gut microbiota also has a long-term impact on both the efficacy and toxicity of anticancer therapies. In particular, it can modulate the concomitant anti-tumour immune response[<xref rid="B223" ref-type="bibr">223</xref>-<xref rid="B227" ref-type="bibr">227</xref>]. Indeed, various pre-clinical mouse models of subcutaneous tumours (melanoma, lung cancer, sarcoma) have suggested that specific crosstalk between bacteria and immune cells may affect responses to anticancer chemotherapies[<xref rid="B223" ref-type="bibr">223</xref>-<xref rid="B227" ref-type="bibr">227</xref>]. In terms of CRC in particular, the efficacy of oxaliplatin, which is a drug routinely used for CRC treatment, has been shown to be strongly reinforced by gut microbiota in mice that were transplanted with MC38 colorectal syngeneic tumours, due to myeloid cells with increased anti-tumour functions[<xref rid="B224" ref-type="bibr">224</xref>]. In addition, it has been described that the gut microbiota contributes to anti-tumour functions of adoptively transferred T cells in several models, including colorectal tumours implanted in mice[<xref rid="B225" ref-type="bibr">225</xref>,<xref rid="B228" ref-type="bibr">228</xref>,<xref rid="B229" ref-type="bibr">229</xref>]. This suggests that the patients&#x02019; microbiota should also be taken into account in future clinical studies involving infusion of autologous anticancer T cells.</p><p>Immune checkpoint therapies are often used in association with chemotherapies and can also be positively or negatively impacted by the gut microbiota in terms of toxicity[<xref rid="B230" ref-type="bibr">230</xref>-<xref rid="B233" ref-type="bibr">233</xref>] and therapeutic effect, as shown for anti-CTLA-4[<xref rid="B231" ref-type="bibr">231</xref>,<xref rid="B233" ref-type="bibr">233</xref>], anti-PD-L1[<xref rid="B234" ref-type="bibr">234</xref>] and anti-PD-1[<xref rid="B235" ref-type="bibr">235</xref>-<xref rid="B237" ref-type="bibr">237</xref>] antibodies. Interestingly, three clinical investigations demonstrated that the gut microbiota can be used to predict responder and non-responder patients to PD-1/PDL-1 immunotherapies in several solid epithelial tumours[<xref rid="B235" ref-type="bibr">235</xref>-<xref rid="B237" ref-type="bibr">237</xref>]. In terms of CRC, many studies have shown the capacity of the gut microbiota to modulate tumour-infiltrating myeloid cell[<xref rid="B238" ref-type="bibr">238</xref>-<xref rid="B240" ref-type="bibr">240</xref>] and T cell responses[<xref rid="B241" ref-type="bibr">241</xref>-<xref rid="B244" ref-type="bibr">244</xref>], while improvement in immunotherapy efficacy by the microbiota is mediated precisely by these immune pathways in solid human epithelial tumours (<italic>e</italic>.<italic>g</italic>., melanoma)[<xref rid="B235" ref-type="bibr">235</xref>-<xref rid="B237" ref-type="bibr">237</xref>]. Moreover, in a subcutaneous CRC mouse model, a positive impact of some microbial species on anti-CTLA-4 immunotherapy was observed[<xref rid="B233" ref-type="bibr">233</xref>]. Given the severe colitis observed in some patients receiving immunotherapies (<italic>e</italic>.<italic>g</italic>., antibodies to CTLA4 and PD-L1) and the role of gut microbes in colitis, it is possible that the gut microbiota influences this toxicity. Investigations are thus needed to elucidate the potential role of the microbiota on immunotherapy efficacy and toxicity in preclinical models and patients. Gut microbiota profiling of CRC patients might be useful in the future to predict treatment responses and/or side effects of cancer chemotherapies and immunotherapies. All these data could lead to &#x0201c;personalized medicine 2.0&#x0201d; that is being developed in an ongoing study investigating the impact of the intestinal microbiome on treatment responses and the toxicity of capecitabine or TAS-102 chemotherapies in patients with metastatic and/or irresectable CRC[<xref rid="B245" ref-type="bibr">245</xref>].</p><p>Perioperative antibiotic prophylaxis strategies targeting the gut microbiota are widely used in colorectal surgery. The aim of such approaches is to prevent both surgical site and wound infections, protecting against potential contamination by the microorganisms that are spread from surgically induced alterations of the intestinal epithelial barrier. However, these antibiotic prophylaxis strategies may also impair the beneficial impact of the gut microbiota on intestinal immune function and healing (for review[<xref rid="B246" ref-type="bibr">246</xref>]). Few studies have investigated the impact that bowel preparation prior to colorectal surgery may have on the mucosa-associated and luminal colonic microbiota[<xref rid="B247" ref-type="bibr">247</xref>]. After the suppression of beneficial bacteria, the host may lose its colonization resistance to pathogens and may have decreased local stimulation of systemic immunity and the healing process[<xref rid="B248" ref-type="bibr">248</xref>,<xref rid="B249" ref-type="bibr">249</xref>]. After surgery, if the commensal microbiota does not repopulate the tract, the situation can lead to the development of pathogenic bacteria such as <italic>C. difficile</italic>[<xref rid="B250" ref-type="bibr">250</xref>]. Moreover, data from animal and human studies have suggested that some of the bacteria present at the anastomotic site may respond to surgical stress by activating virulence pathways, which results in alterations in the healing process. An investigation of the faecal microbiota of patients before and after colorectal surgery for CRC revealed that <italic>Enterococcus faecalis</italic> and <italic>Pseudomonas aeruginosa</italic> were the dominant pathogens present postoperatively in the stools, with a several log-fold increase during the postoperative recovery period[<xref rid="B251" ref-type="bibr">251</xref>]. Postoperative sepsis (<italic>e.g</italic>., anastomotic leakage, perianastomotic abscess) is the most feared complication after colorectal surgery and is responsible for potentially deadly complications and significant alterations in the patient&#x02019;s quality of life. The critical role of the intestinal microbiome in sepsis has been illustrated by studies on germ-free animals, which demonstrated improved survival in these animals compared with conventional animals[<xref rid="B252" ref-type="bibr">252</xref>]. Therefore, the restoration and/or maintenance of a microbiota favouring intestinal healing and preventing surgical site infections after colorectal surgery could be a promising approach for the development of new therapeutic strategies, thus targeting the gut microbiota to improve surgical outcomes. Moreover, the parallel development of tools, such as the &#x0201c;personalized microbiota composition analysis&#x0201d;, to be performed pre- and postoperatively to evaluate the clinical relevance of gut microbiota modulation to positively influence the clinical outcomes and to optimize the perioperative strategies appears promising.</p></sec><sec><title>Limitations of microbial markers and future challenges and directions</title><p>The complexity of the microbiome turns the need for microbial marker-based diagnosis techniques into a real challenge. Numerous studies have reported associations between microbial markers, such as <italic>F. nucleatum</italic>, or colibactin-producing <italic>E. coli</italic>, and CRC, but to date, there is no universal microbial marker defined for CRC detection. Several limitations should be taken into consideration for the future development of new tests. First, the very high variability of the microbiota composition between individuals due to sex, age, diet, lifestyle, genetic background, medication use, ethnicity, or geographical location make finding a universal microbial marker almost impossible. Antibiotic therapy greatly influences the expression of microbial markers and is a critical limitation to microbial marker use. Moreover, standardization in terms sample collection and storage, RNA or metabolite extraction, sample analysis, and data processing is essential to compare studies. If studies that screen for microbiota composition use the same method of 16S rRNA sequencing, the use of metabolomics technologies will require exhaustive standardization between studies. Stary et al[<xref rid="B253" ref-type="bibr">253</xref>] shared a very interesting and detailed list of recommendations for using microbial markers for CRC screening. (1) Any studies should be prepared carefully, taking into account the recommendations and limitations of techniques published previously. (2) Validation of CRC screening markers on specific populations should be encouraged because differences in the gut microbiome are observed in different geographical locations or in different racial/ethnic groups. (3) Whenever possible, conventional culture should be used to confirm the findings from sequencing studies. Particularly, the candidate marker status of species or genes revealed by molecular techniques should be confirmed or refuted by culture and vice versa. Systematic high-throughput culturomics should be developed because cultivation represents an approach that is economical. (4) Screening techniques for CRC risk should evaluate all the known candidate markers, combining particular species, genotoxin production and possibly further strain characteristics whenever relevant. And (5) the potential for practical detection should always be considered. For example, tumour screening, which requires colonoscopy, is costly, uncomfortable for patient and is the gold standard tool for CRC screening. Faecal samples are better non-invasive specimens for developing these microbial-associated-markers. However, faeces are likely to contain a large number of microbial species unrelated to the disease site, which may introduce noise in the detection of potential biomarkers of the disease. Because some bacteria that are associated with CRC, such as <italic>F. nucleatum</italic>, are indigenous to the human oral cavity, analysing the oral microbiome may be an alternative screening method for CRC. Saliva is a biological fluid that may be suitable for biomarker detection. The oral microbial compositions may theoretically reflect the oral and general health status. Flemer et al[<xref rid="B254" ref-type="bibr">254</xref>] found that several oral taxa (such as <italic>Streptococcus</italic> and <italic>Prevotella</italic> spp.) were differentially abundant in CRC patients versus controls. Moreover, they developed a classification model based on the oral swab microbiota that distinguished individuals with CRC or polyps from controls (sensitivity: 53% CRC, 67% polyps; specificity: 96%). Importantly, when data from both the faecal and oral swab microbiota were considered in this model, the sensitivity increased to 76% for CRC and 88% for polyps. In addition to Stary&#x02019;s recommendations, we showed that microbial markers might be different depending on the tumour CRC phenotype[<xref rid="B157" ref-type="bibr">157</xref>]. Moreover, a deeper understanding of the gut microbiota structure and function may help to identify several bacteria that when combined may provide a real CRC-associated microbial signature.</p><p>Finally, the therapeutic efficacy of anticancer drugs could also be improved by active modulation of the gut microbiota through the use of probiotics, prebiotics or specific inhibitors. This perspective is supported by the fact that immunotherapy resistance observed in germ-free mice, in antibiotic-treated mice, and in those that have previously received faecal microbiota transplantation (FMT) from non-responder patients, can be reversed by FMT from responder patients[<xref rid="B233" ref-type="bibr">233</xref>,<xref rid="B235" ref-type="bibr">235</xref>-<xref rid="B237" ref-type="bibr">237</xref>]. Moreover, it has been highlighted that specific bacterial species, such as <italic>Lactobacillus johnsonii</italic>[<xref rid="B226" ref-type="bibr">226</xref>], <italic>Enterococcus hirae</italic>[<xref rid="B223" ref-type="bibr">223</xref>,<xref rid="B226" ref-type="bibr">226</xref>] <italic>Barnesiella intestinihominis</italic>[<xref rid="B223" ref-type="bibr">223</xref>], <italic>Akkermansia muciniphila</italic>[<xref rid="B237" ref-type="bibr">237</xref>], <italic>Bacteroides</italic>[<xref rid="B233" ref-type="bibr">233</xref>] and <italic>Bifidobacterium</italic>[<xref rid="B234" ref-type="bibr">234</xref>,<xref rid="B236" ref-type="bibr">236</xref>] species, are beneficial in this context, which may lead the way to innovative &#x0201c;oncobiotics&#x0201d; strategies that combine anticancer and microbiota-targeting agents.</p></sec></sec><sec><title>CONCLUSION</title><p>In this review, we discuss both predictive and prognostic microbial-associated markers identified in CRC. The faecal-associated microbiota may be dynamically linked to colon cancer, which, in turn, may offer evidence for microflora-associated diagnostic, preventive, and prognostic approaches for CRC. However, it is clear that additional clinical studies are necessary to validate these parameters to improve the diagnosis and therapeutic management of CRC.</p></sec></body><back><fn-group><fn><p>Manuscript source: Invited manuscript</p></fn><fn><p>Specialty type: Gastroenterology and hepatology</p></fn><fn><p>Country of origin: France</p></fn><fn><p>Peer-review report classification</p></fn><fn><p>Grade A (Excellent): A, A</p></fn><fn><p>Grade B (Very good): B</p></fn><fn><p>Grade C (Good): 0</p></fn><fn><p>Grade D (Fair): 0</p></fn><fn><p>Grade E (Poor): 0</p></fn><fn fn-type="COI-statement"><p>Conflict-of-interest statement: None of the authors have any conflicts of interest to declare.</p></fn><fn><p>Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/</p></fn><fn><p>Peer-review started: April 7, 2018</p></fn><fn><p>First decision: April 27, 2018</p></fn><fn><p>Article in press: May 18, 2018</p></fn><fn><p>P- Reviewer: Lorenzo-Z&#x000fa;&#x000f1;iga V, Mayol J, Sunakawa Y S- Editor: Gong ZM L- Editor: A E- Editor: Wang C</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Desantis</surname><given-names>C</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Colorectal cancer statistics, 2014</article-title><source>CA Cancer J Clin</source><year>2014</year><volume>64</volume><fpage>104</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">24639052</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>CJ</given-names></name><name><surname>Bevan</surname><given-names>R</given-names></name></person-group><article-title>The National Health Service Bowel Cancer Screening Program: the early years</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2013</year><volume>7</volume><fpage>421</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">23899282</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RP</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Dunne</surname><given-names>DF</given-names></name><name><surname>Malik</surname><given-names>HZ</given-names></name><name><surname>Fenwick</surname><given-names>SW</given-names></name><name><surname>Poston</surname><given-names>GJ</given-names></name><name><surname>Ghaneh</surname><given-names>P</given-names></name></person-group><article-title>Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases</article-title><source>Br J Surg</source><year>2012</year><volume>99</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">22261895</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connell</surname><given-names>JB</given-names></name><name><surname>Maggard</surname><given-names>MA</given-names></name><name><surname>Ko</surname><given-names>CY</given-names></name></person-group><article-title>Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging</article-title><source>J Natl Cancer Inst</source><year>2004</year><volume>96</volume><fpage>1420</fpage><lpage>1425</lpage><pub-id pub-id-type="pmid">15467030</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winawer</surname><given-names>SJ</given-names></name></person-group><article-title>The history of colorectal cancer screening: a personal perspective</article-title><source>Dig Dis Sci</source><year>2015</year><volume>60</volume><fpage>596</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">25599958</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sears</surname><given-names>CL</given-names></name><name><surname>Garrett</surname><given-names>WS</given-names></name></person-group><article-title>Microbes, microbiota, and colon cancer</article-title><source>Cell Host Microbe</source><year>2014</year><volume>15</volume><fpage>317</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">24629338</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwabe</surname><given-names>RF</given-names></name><name><surname>Jobin</surname><given-names>C</given-names></name></person-group><article-title>The microbiome and cancer</article-title><source>Nat Rev Cancer</source><year>2013</year><volume>13</volume><fpage>800</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">24132111</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name></person-group><article-title>Gut microbiota and colorectal cancer</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2017</year><volume>36</volume><fpage>757</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">28063002</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>YN</given-names></name><name><surname>Fang</surname><given-names>JY</given-names></name></person-group><article-title>Gut Microbiota and Colorectal Cancer</article-title><source>Gastrointest Tumors</source><year>2015</year><volume>2</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">26674881</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagni&#x000e8;re</surname><given-names>J</given-names></name><name><surname>Raisch</surname><given-names>J</given-names></name><name><surname>Veziant</surname><given-names>J</given-names></name><name><surname>Barnich</surname><given-names>N</given-names></name><name><surname>Bonnet</surname><given-names>R</given-names></name><name><surname>Buc</surname><given-names>E</given-names></name><name><surname>Bringer</surname><given-names>MA</given-names></name><name><surname>Pezet</surname><given-names>D</given-names></name><name><surname>Bonnet</surname><given-names>M</given-names></name></person-group><article-title>Gut microbiota imbalance and colorectal cancer</article-title><source>World J Gastroenterol</source><year>2016</year><volume>22</volume><fpage>501</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">26811603</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Darveau</surname><given-names>RP</given-names></name><name><surname>Curtis</surname><given-names>MA</given-names></name></person-group><article-title>The keystone-pathogen hypothesis</article-title><source>Nat Rev Microbiol</source><year>2012</year><volume>10</volume><fpage>717</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">22941505</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>N</given-names></name></person-group><article-title>Effectiveness of Screening Modalities in Colorectal Cancer: A Network Meta-Analysis</article-title><source>Clin Colorectal Cancer</source><year>2017</year><volume>16</volume><fpage>252</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">28687458</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bevan</surname><given-names>R</given-names></name><name><surname>Rutter</surname><given-names>MD</given-names></name></person-group><article-title>Colorectal Cancer Screening-Who, How, and When?</article-title><source>Clin Endosc</source><year>2018</year><volume>51</volume><fpage>37</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">29397655</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>LN</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Collins</surname><given-names>D</given-names></name><name><surname>Yale</surname><given-names>SH</given-names></name></person-group><article-title>Colorectal Cancer Screening</article-title><source>WMJ</source><year>2017</year><volume>116</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">29099566</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjipetrou</surname><given-names>A</given-names></name><name><surname>Anyfantakis</surname><given-names>D</given-names></name><name><surname>Galanakis</surname><given-names>CG</given-names></name><name><surname>Kastanakis</surname><given-names>M</given-names></name><name><surname>Kastanakis</surname><given-names>S</given-names></name></person-group><article-title>Colorectal cancer, screening and primary care: A mini literature review</article-title><source>World J Gastroenterol</source><year>2017</year><volume>23</volume><fpage>6049</fpage><lpage>6058</lpage><pub-id pub-id-type="pmid">28970720</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamzehzadeh</surname><given-names>L</given-names></name><name><surname>Yousefi</surname><given-names>M</given-names></name><name><surname>Ghaffari</surname><given-names>SH</given-names></name></person-group><article-title>Colorectal Cancer Screening: A Comprehensive Review to Recent Non-Invasive Methods</article-title><source>Int J Hematol Oncol Stem Cell Res</source><year>2017</year><volume>11</volume><fpage>250</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">28989593</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Issa</surname><given-names>IA</given-names></name><name><surname>Noureddine</surname><given-names>M</given-names></name></person-group><article-title>Colorectal cancer screening: An updated review of the available options</article-title><source>World J Gastroenterol</source><year>2017</year><volume>23</volume><fpage>5086</fpage><lpage>5096</lpage><pub-id pub-id-type="pmid">28811705</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maida</surname><given-names>M</given-names></name><name><surname>Macaluso</surname><given-names>FS</given-names></name><name><surname>Ianiro</surname><given-names>G</given-names></name><name><surname>Mangiola</surname><given-names>F</given-names></name><name><surname>Sinagra</surname><given-names>E</given-names></name><name><surname>Hold</surname><given-names>G</given-names></name><name><surname>Maida</surname><given-names>C</given-names></name><name><surname>Cammarota</surname><given-names>G</given-names></name><name><surname>Gasbarrini</surname><given-names>A</given-names></name><name><surname>Scarpulla</surname><given-names>G</given-names></name></person-group><article-title>Screening of colorectal cancer: present and future</article-title><source>Expert Rev Anticancer Ther</source><year>2017</year><volume>17</volume><fpage>1131</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">29022408</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leuraud</surname><given-names>K</given-names></name><name><surname>Jezewski-Serra</surname><given-names>D</given-names></name><name><surname>Viguier</surname><given-names>J</given-names></name><name><surname>Salines</surname><given-names>E</given-names></name></person-group><article-title>Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching</article-title><source>Cancer Epidemiol</source><year>2013</year><volume>37</volume><fpage>959</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">24035240</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>MD</given-names></name><name><surname>Nickerson</surname><given-names>C</given-names></name><name><surname>Rees</surname><given-names>CJ</given-names></name><name><surname>Patnick</surname><given-names>J</given-names></name><name><surname>Blanks</surname><given-names>RG</given-names></name></person-group><article-title>Risk factors for adverse events related to polypectomy in the English Bowel Cancer Screening Programme</article-title><source>Endoscopy</source><year>2014</year><volume>46</volume><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">24477363</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><collab>Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM; American College of Gastroenterology</collab><article-title>American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><fpage>739</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">19240699</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pox</surname><given-names>CP</given-names></name></person-group><article-title>Controversies in colorectal cancer screening</article-title><source>Digestion</source><year>2014</year><volume>89</volume><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">25034478</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sali</surname><given-names>L</given-names></name><name><surname>Mascalchi</surname><given-names>M</given-names></name><name><surname>Falchini</surname><given-names>M</given-names></name><name><surname>Ventura</surname><given-names>L</given-names></name><name><surname>Carozzi</surname><given-names>F</given-names></name><name><surname>Castiglione</surname><given-names>G</given-names></name><name><surname>Delsanto</surname><given-names>S</given-names></name><name><surname>Mallardi</surname><given-names>B</given-names></name><name><surname>Mantellini</surname><given-names>P</given-names></name><name><surname>Milani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Reduced and Full-Preparation CT Colonography, Fecal Immunochemical Test, and Colonoscopy for Population Screening of Colorectal Cancer: A Randomized Trial</article-title><source>J Natl Cancer Inst</source><year>2015</year><volume>108</volume><fpage>pii: djv319</fpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pooler</surname><given-names>BD</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Pickhardt</surname><given-names>PJ</given-names></name></person-group><article-title>Indeterminate but Likely Unimportant Extracolonic Findings at Screening CT Colonography (C-RADS Category E3): Incidence and Outcomes Data From a Clinical Screening Program</article-title><source>AJR Am J Roentgenol</source><year>2016</year><volume>207</volume><fpage>996</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">27505184</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Stock</surname><given-names>C</given-names></name><name><surname>Hoffmeister</surname><given-names>M</given-names></name></person-group><article-title>Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies</article-title><source>BMJ</source><year>2014</year><volume>348</volume><fpage>g2467</fpage><pub-id pub-id-type="pmid">24922745</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vleugels</surname><given-names>JL</given-names></name><name><surname>van Lanschot</surname><given-names>MC</given-names></name><name><surname>Dekker</surname><given-names>E</given-names></name></person-group><article-title>Colorectal cancer screening by colonoscopy: putting it into perspective</article-title><source>Dig Endosc</source><year>2016</year><volume>28</volume><fpage>250</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">26257272</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname><given-names>JS</given-names></name><name><surname>Bond</surname><given-names>JH</given-names></name><name><surname>Church</surname><given-names>TR</given-names></name><name><surname>Snover</surname><given-names>DC</given-names></name><name><surname>Bradley</surname><given-names>GM</given-names></name><name><surname>Schuman</surname><given-names>LM</given-names></name><name><surname>Ederer</surname><given-names>F</given-names></name></person-group><article-title>Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study</article-title><source>N Engl J Med</source><year>1993</year><volume>328</volume><fpage>1365</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">8474513</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaukat</surname><given-names>A</given-names></name><name><surname>Mongin</surname><given-names>SJ</given-names></name><name><surname>Geisser</surname><given-names>MS</given-names></name><name><surname>Lederle</surname><given-names>FA</given-names></name><name><surname>Bond</surname><given-names>JH</given-names></name><name><surname>Mandel</surname><given-names>JS</given-names></name><name><surname>Church</surname><given-names>TR</given-names></name></person-group><article-title>Long-term mortality after screening for colorectal cancer</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>1106</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">24047060</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><collab>Holme &#x000d8;, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G</collab><article-title>Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals</article-title><source>Cochrane Database Syst Rev</source><year>2013</year></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heresbach</surname><given-names>D</given-names></name><name><surname>Manfredi</surname><given-names>S</given-names></name><name><surname>D&#x02019;halluin</surname><given-names>PN</given-names></name><name><surname>Bretagne</surname><given-names>JF</given-names></name><name><surname>Branger</surname><given-names>B</given-names></name></person-group><article-title>Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test</article-title><source>Eur J Gastroenterol Hepatol</source><year>2006</year><volume>18</volume><fpage>427</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">16538116</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitk&#x000e4;niemi</surname><given-names>J</given-names></name><name><surname>Sepp&#x000e4;</surname><given-names>K</given-names></name><name><surname>Hakama</surname><given-names>M</given-names></name><name><surname>Malminiemi</surname><given-names>O</given-names></name><name><surname>Palva</surname><given-names>T</given-names></name><name><surname>Vuoristo</surname><given-names>MS</given-names></name><name><surname>J&#x000e4;rvinen</surname><given-names>H</given-names></name><name><surname>Paimela</surname><given-names>H</given-names></name><name><surname>Pikkarainen</surname><given-names>P</given-names></name><name><surname>Anttila</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effectiveness of screening for colorectal cancer with a faecal occult-blood test, in Finland</article-title><source>BMJ Open Gastroenterol</source><year>2015</year><volume>2</volume><fpage>e000034</fpage></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kati&#x0010d;i&#x00107;</surname><given-names>M</given-names></name><name><surname>Antoljak</surname><given-names>N</given-names></name><name><surname>Kujund&#x0017e;i&#x00107;</surname><given-names>M</given-names></name><name><surname>Stameni&#x00107;</surname><given-names>V</given-names></name><name><surname>Skoko Poljak</surname><given-names>D</given-names></name><name><surname>Kramari&#x00107;</surname><given-names>D</given-names></name><name><surname>Stimac</surname><given-names>D</given-names></name><name><surname>Strnad Pe&#x00161;ikan</surname><given-names>M</given-names></name><name><surname>Samija</surname><given-names>M</given-names></name><name><surname>Ebling</surname><given-names>Z</given-names></name></person-group><article-title>Results of National Colorectal Cancer Screening Program in Croatia (2007-2011)</article-title><source>World J Gastroenterol</source><year>2012</year><volume>18</volume><fpage>4300</fpage><lpage>4307</lpage><pub-id pub-id-type="pmid">22969192</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>RJ</given-names></name><name><surname>McClements</surname><given-names>PL</given-names></name><name><surname>Libby</surname><given-names>G</given-names></name><name><surname>Black</surname><given-names>R</given-names></name><name><surname>Morton</surname><given-names>C</given-names></name><name><surname>Birrell</surname><given-names>J</given-names></name><name><surname>Mowat</surname><given-names>NA</given-names></name><name><surname>Wilson</surname><given-names>JA</given-names></name><name><surname>Kenicer</surname><given-names>M</given-names></name><name><surname>Carey</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer</article-title><source>Gut</source><year>2009</year><volume>58</volume><fpage>530</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">19036949</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rex</surname><given-names>DK</given-names></name><name><surname>Boland</surname><given-names>CR</given-names></name><name><surname>Dominitz</surname><given-names>JA</given-names></name><name><surname>Giardiello</surname><given-names>FM</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Kaltenbach</surname><given-names>T</given-names></name><name><surname>Levin</surname><given-names>TR</given-names></name><name><surname>Lieberman</surname><given-names>D</given-names></name><name><surname>Robertson</surname><given-names>DJ</given-names></name></person-group><article-title>Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer</article-title><source>Gastroenterology</source><year>2017</year><volume>153</volume><fpage>307</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">28600072</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Nicolas</surname><given-names>A</given-names></name><name><surname>Ferrandez</surname><given-names>A</given-names></name><name><surname>Lanas</surname><given-names>A</given-names></name></person-group><article-title>Colorectal cancer population screening programs worldwide in 2016: An update</article-title><source>World J Gastroenterol</source><year>2017</year><volume>23</volume><fpage>3632</fpage><lpage>3642</lpage><pub-id pub-id-type="pmid">28611516</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewitson</surname><given-names>P</given-names></name><name><surname>Glasziou</surname><given-names>P</given-names></name><name><surname>Irwig</surname><given-names>L</given-names></name><name><surname>Towler</surname><given-names>B</given-names></name><name><surname>Watson</surname><given-names>E</given-names></name></person-group><article-title>Screening for colorectal cancer using the faecal occult blood test, Hemoccult</article-title><source>Cochrane Database Syst Rev</source><year>2007</year></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name></person-group><article-title>Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis</article-title><source>Int J Cancer</source><year>2012</year><volume>131</volume><fpage>1837</fpage><lpage>1845</lpage><pub-id pub-id-type="pmid">22261915</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haug</surname><given-names>U</given-names></name><name><surname>Rothenbacher</surname><given-names>D</given-names></name><name><surname>Wente</surname><given-names>MN</given-names></name><name><surname>Seiler</surname><given-names>CM</given-names></name><name><surname>Stegmaier</surname><given-names>C</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name></person-group><article-title>Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients</article-title><source>Br J Cancer</source><year>2007</year><volume>96</volume><fpage>1329</fpage><lpage>1334</lpage><pub-id pub-id-type="pmid">17406361</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonus</surname><given-names>C</given-names></name><name><surname>Sellinger</surname><given-names>M</given-names></name><name><surname>Koss</surname><given-names>K</given-names></name><name><surname>Neupert</surname><given-names>G</given-names></name></person-group><article-title>Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis</article-title><source>World J Gastroenterol</source><year>2012</year><volume>18</volume><fpage>4004</fpage><lpage>4011</lpage><pub-id pub-id-type="pmid">22912551</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><collab>Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group</collab><article-title>Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2704</fpage><lpage>2714</lpage><pub-id pub-id-type="pmid">15616205</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreuders</surname><given-names>EH</given-names></name><name><surname>Grobbee</surname><given-names>EJ</given-names></name><name><surname>Spaander</surname><given-names>MC</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name></person-group><article-title>Advances in Fecal Tests for Colorectal Cancer Screening</article-title><source>Curr Treat Options Gastroenterol</source><year>2016</year><volume>14</volume><fpage>152</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">26825703</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlquist</surname><given-names>DA</given-names></name></person-group><article-title>Multi-target stool DNA test: a new high bar for noninvasive screening</article-title><source>Dig Dis Sci</source><year>2015</year><volume>60</volume><fpage>623</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">25492503</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhaliwal</surname><given-names>A</given-names></name><name><surname>Vlachostergios</surname><given-names>PJ</given-names></name><name><surname>Oikonomou</surname><given-names>KG</given-names></name><name><surname>Moshenyat</surname><given-names>Y</given-names></name></person-group><article-title>Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives</article-title><source>World J Gastrointest Oncol</source><year>2015</year><volume>7</volume><fpage>178</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">26483873</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imperiale</surname><given-names>TF</given-names></name><name><surname>Ransohoff</surname><given-names>DF</given-names></name><name><surname>Itzkowitz</surname><given-names>SH</given-names></name><name><surname>Levin</surname><given-names>TR</given-names></name><name><surname>Lavin</surname><given-names>P</given-names></name><name><surname>Lidgard</surname><given-names>GP</given-names></name><name><surname>Ahlquist</surname><given-names>DA</given-names></name><name><surname>Berger</surname><given-names>BM</given-names></name></person-group><article-title>Multitarget stool DNA testing for colorectal-cancer screening</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>1287</fpage><lpage>1297</lpage><pub-id pub-id-type="pmid">24645800</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>AB</given-names></name><name><surname>Zauber</surname><given-names>AG</given-names></name><name><surname>Rutter</surname><given-names>CM</given-names></name><name><surname>Naber</surname><given-names>SK</given-names></name><name><surname>Doria-Rose</surname><given-names>VP</given-names></name><name><surname>Pabiniak</surname><given-names>C</given-names></name><name><surname>Johanson</surname><given-names>C</given-names></name><name><surname>Fischer</surname><given-names>SE</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name><name><surname>Kuntz</surname><given-names>KM</given-names></name></person-group><article-title>Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force</article-title><source>JAMA</source><year>2016</year><volume>315</volume><fpage>2595</fpage><lpage>2609</lpage><pub-id pub-id-type="pmid">27305518</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauptman</surname><given-names>N</given-names></name><name><surname>Glava&#x0010d;</surname><given-names>D</given-names></name></person-group><article-title>Colorectal Cancer Blood-Based Biomarkers</article-title><source>Gastroenterol Res Pract</source><year>2017</year><volume>2017</volume><fpage>2195361</fpage><pub-id pub-id-type="pmid">29147109</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hench</surname><given-names>IB</given-names></name><name><surname>Hench</surname><given-names>J</given-names></name><name><surname>Tolnay</surname><given-names>M</given-names></name></person-group><article-title>Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer</article-title><source>Front Med (Lausanne)</source><year>2018</year><volume>5</volume><fpage>9</fpage><pub-id pub-id-type="pmid">29441349</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>55632</fpage><lpage>55645</lpage><pub-id pub-id-type="pmid">28903450</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordg&#x000e5;rd</surname><given-names>O</given-names></name><name><surname>Tjensvoll</surname><given-names>K</given-names></name><name><surname>Gilje</surname><given-names>B</given-names></name><name><surname>S&#x000f8;reide</surname><given-names>K</given-names></name></person-group><article-title>Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer</article-title><source>Br J Surg</source><year>2018</year><volume>105</volume><fpage>e110</fpage><lpage>e120</lpage><pub-id pub-id-type="pmid">29341153</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>WL</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Lee</surname><given-names>YM</given-names></name><name><surname>Ho</surname><given-names>JW</given-names></name></person-group><article-title>The impact of postoperative complications on long-term outcomes following curative resection for colorectal cancer</article-title><source>Ann Surg Oncol</source><year>2007</year><volume>14</volume><fpage>2559</fpage><lpage>2566</lpage><pub-id pub-id-type="pmid">17522945</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McArdle</surname><given-names>CS</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name><name><surname>Hole</surname><given-names>DJ</given-names></name></person-group><article-title>Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer</article-title><source>Br J Surg</source><year>2005</year><volume>92</volume><fpage>1150</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">16035134</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nespoli</surname><given-names>A</given-names></name><name><surname>Gianotti</surname><given-names>L</given-names></name><name><surname>Totis</surname><given-names>M</given-names></name><name><surname>Bovo</surname><given-names>G</given-names></name><name><surname>Nespoli</surname><given-names>L</given-names></name><name><surname>Chiodini</surname><given-names>P</given-names></name><name><surname>Brivio</surname><given-names>F</given-names></name></person-group><article-title>Correlation between postoperative infections and long-term survival after colorectal resection for cancer</article-title><source>Tumori</source><year>2004</year><volume>90</volume><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">15656334</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mynster</surname><given-names>T</given-names></name><name><surname>Christensen</surname><given-names>IJ</given-names></name><name><surname>Moesgaard</surname><given-names>F</given-names></name><name><surname>Nielsen</surname><given-names>HJ</given-names></name></person-group><article-title>Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group</article-title><source>Br J Surg</source><year>2000</year><volume>87</volume><fpage>1553</fpage><lpage>1562</lpage><pub-id pub-id-type="pmid">11091245</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adloff</surname><given-names>M</given-names></name><name><surname>Arnaud</surname><given-names>JP</given-names></name><name><surname>Ollier</surname><given-names>JC</given-names></name><name><surname>Schloegel</surname><given-names>M</given-names></name></person-group><article-title>[Can the prognosis of patients treated surgically in cancer of the rectum or colon be improved by follow-up? Prospective study of 909 patients]</article-title><source>Chirurgie</source><year>1989</year><volume>115</volume><fpage>228</fpage><lpage>36; discussion 236-7</lpage><pub-id pub-id-type="pmid">2805932</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moertel</surname><given-names>CG</given-names></name><name><surname>Fleming</surname><given-names>TR</given-names></name><name><surname>Macdonald</surname><given-names>JS</given-names></name><name><surname>Haller</surname><given-names>DG</given-names></name><name><surname>Laurie</surname><given-names>JA</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Ungerleider</surname><given-names>JS</given-names></name><name><surname>Emerson</surname><given-names>WA</given-names></name><name><surname>Tormey</surname><given-names>DC</given-names></name><name><surname>Glick</surname><given-names>JH</given-names></name></person-group><article-title>Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma</article-title><source>N Engl J Med</source><year>1990</year><volume>322</volume><fpage>352</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">2300087</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname><given-names>FL</given-names></name><name><surname>Stewart</surname><given-names>AK</given-names></name><name><surname>Norton</surname><given-names>HJ</given-names></name></person-group><article-title>A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients</article-title><source>Ann Surg</source><year>2002</year><volume>236</volume><fpage>416</fpage><lpage>21; discussion 421</lpage><pub-id pub-id-type="pmid">12368669</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compton</surname><given-names>CC</given-names></name><name><surname>Fielding</surname><given-names>LP</given-names></name><name><surname>Burgart</surname><given-names>LJ</given-names></name><name><surname>Conley</surname><given-names>B</given-names></name><name><surname>Cooper</surname><given-names>HS</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Hammond</surname><given-names>ME</given-names></name><name><surname>Henson</surname><given-names>DE</given-names></name><name><surname>Hutter</surname><given-names>RV</given-names></name><name><surname>Nagle</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999</article-title><source>Arch Pathol Lab Med</source><year>2000</year><volume>124</volume><fpage>979</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">10888773</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compton</surname><given-names>CC</given-names></name></person-group><article-title>Colorectal carcinoma: diagnostic, prognostic, and molecular features</article-title><source>Mod Pathol</source><year>2003</year><volume>16</volume><fpage>376</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">12692203</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huh</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name></person-group><article-title>Lymphovascular or perineural invasion may predict lymph node metastasis in patients with T1 and T2 colorectal cancer</article-title><source>J Gastrointest Surg</source><year>2010</year><volume>14</volume><fpage>1074</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">20431977</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebig</surname><given-names>C</given-names></name><name><surname>Ayala</surname><given-names>G</given-names></name><name><surname>Wilks</surname><given-names>J</given-names></name><name><surname>Verstovsek</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Agarwal</surname><given-names>N</given-names></name><name><surname>Berger</surname><given-names>DH</given-names></name><name><surname>Albo</surname><given-names>D</given-names></name></person-group><article-title>Perineural invasion is an independent predictor of outcome in colorectal cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>5131</fpage><lpage>5137</lpage><pub-id pub-id-type="pmid">19738119</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Mitomi</surname><given-names>H</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Ohtani</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name></person-group><article-title>Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer</article-title><source>Hepatogastroenterology</source><year>2005</year><volume>52</volume><fpage>1432</fpage><lpage>1435</lpage><pub-id pub-id-type="pmid">16201089</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlobec</surname><given-names>I</given-names></name><name><surname>Lugli</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>K</given-names></name><name><surname>Roth</surname><given-names>S</given-names></name><name><surname>Minoo</surname><given-names>P</given-names></name><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>Terracciano</surname><given-names>L</given-names></name><name><surname>Jass</surname><given-names>JR</given-names></name></person-group><article-title>Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer</article-title><source>J Pathol</source><year>2007</year><volume>212</volume><fpage>260</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">17516584</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purdie</surname><given-names>CA</given-names></name><name><surname>Piris</surname><given-names>J</given-names></name></person-group><article-title>Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma</article-title><source>Histopathology</source><year>2000</year><volume>36</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">10672056</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>YB</given-names></name><name><surname>Chun</surname><given-names>HK</given-names></name><name><surname>Yun</surname><given-names>HR</given-names></name><name><surname>Kim</surname><given-names>HC</given-names></name><name><surname>Yun</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>WY</given-names></name></person-group><article-title>Histological grade predicts survival time associated with recurrence after resection for colorectal cancer</article-title><source>Hepatogastroenterology</source><year>2009</year><volume>56</volume><fpage>1335</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">19950787</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarbo</surname><given-names>RJ</given-names></name><name><surname>Nakhleh</surname><given-names>RE</given-names></name><name><surname>Brown</surname><given-names>RD</given-names></name><name><surname>Kubus</surname><given-names>JJ</given-names></name><name><surname>Ma</surname><given-names>CK</given-names></name><name><surname>Mackowiak</surname><given-names>P</given-names></name></person-group><article-title>Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry</article-title><source>Cancer</source><year>1997</year><volume>79</volume><fpage>2073</fpage><lpage>2086</lpage><pub-id pub-id-type="pmid">9179053</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtani</surname><given-names>H</given-names></name></person-group><article-title>Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer</article-title><source>Cancer Immun</source><year>2007</year><volume>7</volume><fpage>4</fpage><pub-id pub-id-type="pmid">17311363</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>K</given-names></name><name><surname>Zlobec</surname><given-names>I</given-names></name><name><surname>Tornillo</surname><given-names>L</given-names></name><name><surname>Terracciano</surname><given-names>L</given-names></name><name><surname>Jass</surname><given-names>JR</given-names></name><name><surname>Lugli</surname><given-names>A</given-names></name></person-group><article-title>Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway</article-title><source>Eur J Cancer</source><year>2007</year><volume>43</volume><fpage>624</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">17223543</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jantscheff</surname><given-names>P</given-names></name><name><surname>Terracciano</surname><given-names>L</given-names></name><name><surname>Lowy</surname><given-names>A</given-names></name><name><surname>Glatz-Krieger</surname><given-names>K</given-names></name><name><surname>Grunert</surname><given-names>F</given-names></name><name><surname>Micheel</surname><given-names>B</given-names></name><name><surname>Br&#x000fc;mmer</surname><given-names>J</given-names></name><name><surname>Laffer</surname><given-names>U</given-names></name><name><surname>Metzger</surname><given-names>U</given-names></name><name><surname>Herrmann</surname><given-names>R</given-names></name><etal/></person-group><article-title>Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>3638</fpage><lpage>3646</lpage><pub-id pub-id-type="pmid">14512395</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popat</surname><given-names>S</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name></person-group><article-title>A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis</article-title><source>Eur J Cancer</source><year>2005</year><volume>41</volume><fpage>2060</fpage><lpage>2070</lpage><pub-id pub-id-type="pmid">16125380</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><collab>Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, Jessup JM, Loda M, Summerhayes IC</collab><article-title>The DCC protein and prognosis in colorectal cancer</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>1727</fpage><lpage>1732</lpage><pub-id pub-id-type="pmid">8929264</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwandner</surname><given-names>O</given-names></name><name><surname>Schiedeck</surname><given-names>TH</given-names></name><name><surname>Bruch</surname><given-names>HP</given-names></name><name><surname>Duchrow</surname><given-names>M</given-names></name><name><surname>Windhoevel</surname><given-names>U</given-names></name><name><surname>Broll</surname><given-names>R</given-names></name></person-group><article-title>p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer</article-title><source>Eur J Cancer</source><year>2000</year><volume>36</volume><fpage>348</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">10708936</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulder</surname><given-names>JW</given-names></name><name><surname>Kruyt</surname><given-names>PM</given-names></name><name><surname>Sewnath</surname><given-names>M</given-names></name><name><surname>Oosting</surname><given-names>J</given-names></name><name><surname>Seldenrijk</surname><given-names>CA</given-names></name><name><surname>Weidema</surname><given-names>WF</given-names></name><name><surname>Offerhaus</surname><given-names>GJ</given-names></name><name><surname>Pals</surname><given-names>ST</given-names></name></person-group><article-title>Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins</article-title><source>Lancet</source><year>1994</year><volume>344</volume><fpage>1470</fpage><lpage>1472</lpage><pub-id pub-id-type="pmid">7526103</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koopman</surname><given-names>M</given-names></name><name><surname>Venderbosch</surname><given-names>S</given-names></name><name><surname>Nagtegaal</surname><given-names>ID</given-names></name><name><surname>van Krieken</surname><given-names>JH</given-names></name><name><surname>Punt</surname><given-names>CJ</given-names></name></person-group><article-title>A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?</article-title><source>Eur J Cancer</source><year>2009</year><volume>45</volume><fpage>1935</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">19473832</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gryfe</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Hsieh</surname><given-names>ET</given-names></name><name><surname>Aronson</surname><given-names>MD</given-names></name><name><surname>Holowaty</surname><given-names>EJ</given-names></name><name><surname>Bull</surname><given-names>SB</given-names></name><name><surname>Redston</surname><given-names>M</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name></person-group><article-title>Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10631274</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankel</surname><given-names>TL</given-names></name><name><surname>Vakiani</surname><given-names>E</given-names></name><name><surname>Nathan</surname><given-names>H</given-names></name><name><surname>DeMatteo</surname><given-names>RP</given-names></name><name><surname>Kingham</surname><given-names>TP</given-names></name><name><surname>Allen</surname><given-names>PJ</given-names></name><name><surname>Jarnagin</surname><given-names>WR</given-names></name><name><surname>Kemeny</surname><given-names>NE</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>D&#x02019;Angelica</surname><given-names>MI</given-names></name></person-group><article-title>Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases</article-title><source>Cancer</source><year>2017</year><volume>123</volume><fpage>568</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">27737491</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><collab>Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA Jr, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA</collab><article-title>Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases</article-title><source>Cancer</source><year>2013</year><volume>119</volume><fpage>4137</fpage><lpage>4144</lpage><pub-id pub-id-type="pmid">24104864</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stremitzer</surname><given-names>S</given-names></name><name><surname>Stift</surname><given-names>J</given-names></name><name><surname>Gruenberger</surname><given-names>B</given-names></name><name><surname>Tamandl</surname><given-names>D</given-names></name><name><surname>Aschacher</surname><given-names>T</given-names></name><name><surname>Wolf</surname><given-names>B</given-names></name><name><surname>Wrba</surname><given-names>F</given-names></name><name><surname>Gruenberger</surname><given-names>T</given-names></name></person-group><article-title>KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab</article-title><source>Br J Surg</source><year>2012</year><volume>99</volume><fpage>1575</fpage><lpage>1582</lpage><pub-id pub-id-type="pmid">23027075</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vauthey</surname><given-names>JN</given-names></name><name><surname>Zimmitti</surname><given-names>G</given-names></name><name><surname>Kopetz</surname><given-names>SE</given-names></name><name><surname>Shindoh</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>SS</given-names></name><name><surname>Andreou</surname><given-names>A</given-names></name><name><surname>Curley</surname><given-names>SA</given-names></name><name><surname>Aloia</surname><given-names>TA</given-names></name><name><surname>Maru</surname><given-names>DM</given-names></name></person-group><article-title>RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases</article-title><source>Ann Surg</source><year>2013</year><volume>258</volume><fpage>619</fpage><lpage>26; discussion 626-7</lpage><pub-id pub-id-type="pmid">24018645</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richman</surname><given-names>SD</given-names></name><name><surname>Seymour</surname><given-names>MT</given-names></name><name><surname>Chambers</surname><given-names>P</given-names></name><name><surname>Elliott</surname><given-names>F</given-names></name><name><surname>Daly</surname><given-names>CL</given-names></name><name><surname>Meade</surname><given-names>AM</given-names></name><name><surname>Taylor</surname><given-names>G</given-names></name><name><surname>Barrett</surname><given-names>JH</given-names></name><name><surname>Quirke</surname><given-names>P</given-names></name></person-group><article-title>KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>5931</fpage><lpage>5937</lpage><pub-id pub-id-type="pmid">19884549</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>B</given-names></name><name><surname>Kopetz</surname><given-names>S</given-names></name><name><surname>Tie</surname><given-names>J</given-names></name><name><surname>Gibbs</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>ZQ</given-names></name><name><surname>Lieu</surname><given-names>CH</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Maru</surname><given-names>DM</given-names></name><name><surname>Sieber</surname><given-names>O</given-names></name><name><surname>Desai</surname><given-names>J</given-names></name></person-group><article-title>Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>4623</fpage><lpage>4632</lpage><pub-id pub-id-type="pmid">21456008</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>K&#x000f6;hne</surname><given-names>CH</given-names></name><name><surname>L&#x000e1;ng</surname><given-names>I</given-names></name><name><surname>Folprecht</surname><given-names>G</given-names></name><name><surname>Nowacki</surname><given-names>MP</given-names></name><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Shchepotin</surname><given-names>I</given-names></name><name><surname>Maurel</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Tejpar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>2011</fpage><lpage>2019</lpage><pub-id pub-id-type="pmid">21502544</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaf&#x000e0;</surname><given-names>R</given-names></name><name><surname>Maestri</surname><given-names>I</given-names></name><name><surname>Matteuzzi</surname><given-names>M</given-names></name><name><surname>Santini</surname><given-names>A</given-names></name><name><surname>Ferretti</surname><given-names>S</given-names></name><name><surname>Cavazzini</surname><given-names>L</given-names></name><name><surname>Lanza</surname><given-names>G</given-names></name></person-group><article-title>Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability</article-title><source>Cancer</source><year>2000</year><volume>89</volume><fpage>2025</fpage><lpage>2037</lpage><pub-id pub-id-type="pmid">11066042</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benatti</surname><given-names>P</given-names></name><name><surname>Gaf&#x000e0;</surname><given-names>R</given-names></name><name><surname>Barana</surname><given-names>D</given-names></name><name><surname>Marino</surname><given-names>M</given-names></name><name><surname>Scarselli</surname><given-names>A</given-names></name><name><surname>Pedroni</surname><given-names>M</given-names></name><name><surname>Maestri</surname><given-names>I</given-names></name><name><surname>Guerzoni</surname><given-names>L</given-names></name><name><surname>Roncucci</surname><given-names>L</given-names></name><name><surname>Menigatti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Microsatellite instability and colorectal cancer prognosis</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>8332</fpage><lpage>8340</lpage><pub-id pub-id-type="pmid">16322293</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendardaf</surname><given-names>R</given-names></name><name><surname>Lamlum</surname><given-names>H</given-names></name><name><surname>Ristam&#x000e4;ki</surname><given-names>R</given-names></name><name><surname>Korkeila</surname><given-names>E</given-names></name><name><surname>Syrj&#x000e4;nen</surname><given-names>K</given-names></name><name><surname>Pyrh&#x000f6;nen</surname><given-names>S</given-names></name></person-group><article-title>Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer</article-title><source>Tumour Biol</source><year>2007</year><volume>28</volume><fpage>212</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">17717427</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carethers</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>EJ</given-names></name><name><surname>Behling</surname><given-names>CA</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Tajima</surname><given-names>A</given-names></name><name><surname>Doctolero</surname><given-names>RT</given-names></name><name><surname>Cabrera</surname><given-names>BL</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Arnold</surname><given-names>CA</given-names></name><name><surname>Miyai</surname><given-names>K</given-names></name><etal/></person-group><article-title>Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">14762775</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jover</surname><given-names>R</given-names></name><name><surname>Zapater</surname><given-names>P</given-names></name><name><surname>Castells</surname><given-names>A</given-names></name><name><surname>Llor</surname><given-names>X</given-names></name><name><surname>Andreu</surname><given-names>M</given-names></name><name><surname>Cubiella</surname><given-names>J</given-names></name><name><surname>Pi&#x000f1;ol</surname><given-names>V</given-names></name><name><surname>Xicola</surname><given-names>RM</given-names></name><name><surname>Bujanda</surname><given-names>L</given-names></name><name><surname>Re&#x000f1;&#x000e9;</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer</article-title><source>Gut</source><year>2006</year><volume>55</volume><fpage>848</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">16299036</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribic</surname><given-names>CM</given-names></name><name><surname>Sargent</surname><given-names>DJ</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>French</surname><given-names>AJ</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name><name><surname>Gryfe</surname><given-names>R</given-names></name><name><surname>Shepherd</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">12867608</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llosa</surname><given-names>NJ</given-names></name><name><surname>Cruise</surname><given-names>M</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Wicks</surname><given-names>EC</given-names></name><name><surname>Hechenbleikner</surname><given-names>EM</given-names></name><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Blosser</surname><given-names>RL</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Luber</surname><given-names>BS</given-names></name><etal/></person-group><article-title>The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints</article-title><source>Cancer Discov</source><year>2015</year><volume>5</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">25358689</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amado</surname><given-names>RG</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Freeman</surname><given-names>DJ</given-names></name><name><surname>Juan</surname><given-names>T</given-names></name><name><surname>Sikorski</surname><given-names>R</given-names></name><name><surname>Suggs</surname><given-names>S</given-names></name><name><surname>Radinsky</surname><given-names>R</given-names></name><etal/></person-group><article-title>Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1626</fpage><lpage>1634</lpage><pub-id pub-id-type="pmid">18316791</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Oliner</surname><given-names>KS</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Burkes</surname><given-names>R</given-names></name><name><surname>Barugel</surname><given-names>M</given-names></name><name><surname>Humblet</surname><given-names>Y</given-names></name><name><surname>Bodoky</surname><given-names>G</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Jassem</surname><given-names>J</given-names></name><etal/></person-group><article-title>Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>1023</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">24024839</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>K&#x000f6;hne</surname><given-names>CH</given-names></name><name><surname>Hitre</surname><given-names>E</given-names></name><name><surname>Zaluski</surname><given-names>J</given-names></name><name><surname>Chang Chien</surname><given-names>CR</given-names></name><name><surname>Makhson</surname><given-names>A</given-names></name><name><surname>D&#x02019;Haens</surname><given-names>G</given-names></name><name><surname>Pint&#x000e9;r</surname><given-names>T</given-names></name><name><surname>Lim</surname><given-names>R</given-names></name><name><surname>Bodoky</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>1408</fpage><lpage>1417</lpage><pub-id pub-id-type="pmid">19339720</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrantonio</surname><given-names>F</given-names></name><name><surname>Petrelli</surname><given-names>F</given-names></name><name><surname>Coinu</surname><given-names>A</given-names></name><name><surname>Di Bartolomeo</surname><given-names>M</given-names></name><name><surname>Borgonovo</surname><given-names>K</given-names></name><name><surname>Maggi</surname><given-names>C</given-names></name><name><surname>Cabiddu</surname><given-names>M</given-names></name><name><surname>Iacovelli</surname><given-names>R</given-names></name><name><surname>Bossi</surname><given-names>I</given-names></name><name><surname>Lonati</surname><given-names>V</given-names></name><etal/></person-group><article-title>Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis</article-title><source>Eur J Cancer</source><year>2015</year><volume>51</volume><fpage>587</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">25673558</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>A</given-names></name><name><surname>Dias</surname><given-names>MM</given-names></name><name><surname>Wiese</surname><given-names>MD</given-names></name><name><surname>Kichenadasse</surname><given-names>G</given-names></name><name><surname>McKinnon</surname><given-names>RA</given-names></name><name><surname>Karapetis</surname><given-names>CS</given-names></name><name><surname>Sorich</surname><given-names>MJ</given-names></name></person-group><article-title>Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer</article-title><source>Br J Cancer</source><year>2015</year><volume>112</volume><fpage>1888</fpage><lpage>1894</lpage><pub-id pub-id-type="pmid">25989278</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Brummelen</surname><given-names>EMJ</given-names></name><name><surname>de Boer</surname><given-names>A</given-names></name><name><surname>Beijnen</surname><given-names>JH</given-names></name><name><surname>Schellens</surname><given-names>JHM</given-names></name></person-group><article-title><italic>BRAF</italic> Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies</article-title><source>Oncologist</source><year>2017</year><volume>22</volume><fpage>864</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">28576857</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMillan</surname><given-names>DC</given-names></name><name><surname>Wotherspoon</surname><given-names>HA</given-names></name><name><surname>Fearon</surname><given-names>KC</given-names></name><name><surname>Sturgeon</surname><given-names>C</given-names></name><name><surname>Cooke</surname><given-names>TG</given-names></name><name><surname>McArdle</surname><given-names>CS</given-names></name></person-group><article-title>A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery</article-title><source>Am J Surg</source><year>1995</year><volume>170</volume><fpage>319</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">7573721</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canna</surname><given-names>K</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name><name><surname>McKee</surname><given-names>RF</given-names></name><name><surname>McNicol</surname><given-names>AM</given-names></name><name><surname>Horgan</surname><given-names>PG</given-names></name><name><surname>McArdle</surname><given-names>CS</given-names></name></person-group><article-title>Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer</article-title><source>Br J Cancer</source><year>2004</year><volume>90</volume><fpage>1707</fpage><lpage>1709</lpage><pub-id pub-id-type="pmid">15150596</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crozier</surname><given-names>JE</given-names></name><name><surname>McKee</surname><given-names>RF</given-names></name><name><surname>McArdle</surname><given-names>CS</given-names></name><name><surname>Angerson</surname><given-names>WJ</given-names></name><name><surname>Anderson</surname><given-names>JH</given-names></name><name><surname>Horgan</surname><given-names>PG</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name></person-group><article-title>The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer</article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><fpage>1833</fpage><lpage>1836</lpage><pub-id pub-id-type="pmid">16721360</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Shaiba</surname><given-names>R</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name><name><surname>Angerson</surname><given-names>WJ</given-names></name><name><surname>Leen</surname><given-names>E</given-names></name><name><surname>McArdle</surname><given-names>CS</given-names></name><name><surname>Horgan</surname><given-names>P</given-names></name></person-group><article-title>The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases</article-title><source>Br J Cancer</source><year>2004</year><volume>91</volume><fpage>205</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">15213726</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMillan</surname><given-names>DC</given-names></name><name><surname>Watson</surname><given-names>WS</given-names></name><name><surname>O&#x02019;Gorman</surname><given-names>P</given-names></name><name><surname>Preston</surname><given-names>T</given-names></name><name><surname>Scott</surname><given-names>HR</given-names></name><name><surname>McArdle</surname><given-names>CS</given-names></name></person-group><article-title>Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss</article-title><source>Nutr Cancer</source><year>2001</year><volume>39</volume><fpage>210</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">11759282</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cengiz</surname><given-names>O</given-names></name><name><surname>Kocer</surname><given-names>B</given-names></name><name><surname>S&#x000fc;rmeli</surname><given-names>S</given-names></name><name><surname>Santicky</surname><given-names>MJ</given-names></name><name><surname>Soran</surname><given-names>A</given-names></name></person-group><article-title>Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma?</article-title><source>Med Sci Monit</source><year>2006</year><volume>12</volume><fpage>CR240</fpage><lpage>CR247</lpage><pub-id pub-id-type="pmid">16733481</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMillan</surname><given-names>DC</given-names></name><name><surname>Canna</surname><given-names>K</given-names></name><name><surname>McArdle</surname><given-names>CS</given-names></name></person-group><article-title>Systemic inflammatory response predicts survival following curative resection of colorectal cancer</article-title><source>Br J Surg</source><year>2003</year><volume>90</volume><fpage>215</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">12555298</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>S</given-names></name><name><surname>Namiki</surname><given-names>M</given-names></name><name><surname>Takahara</surname><given-names>S</given-names></name><name><surname>Matsumiya</surname><given-names>K</given-names></name><name><surname>Kondoh</surname><given-names>N</given-names></name><name><surname>Kokado</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Okuyama</surname><given-names>A</given-names></name></person-group><article-title>Serum HGF levels in acute renal rejection after living related renal transplantation</article-title><source>Transpl Int</source><year>1996</year><volume>9</volume><fpage>151</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">8639257</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>LE</given-names></name><name><surname>Guillem</surname><given-names>JG</given-names></name><name><surname>Paty</surname><given-names>P</given-names></name><name><surname>Cohen</surname><given-names>AM</given-names></name></person-group><article-title>Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients</article-title><source>J Am Coll Surg</source><year>1997</year><volume>185</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">9208961</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hohenberger</surname><given-names>P</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name><name><surname>Gerneth</surname><given-names>T</given-names></name><name><surname>Herfarth</surname><given-names>C</given-names></name></person-group><article-title>Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis</article-title><source>Ann Surg</source><year>1994</year><volume>219</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">8129484</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malapelle</surname><given-names>U</given-names></name><name><surname>Mayo de-Las-Casas</surname><given-names>C</given-names></name><name><surname>Rocco</surname><given-names>D</given-names></name><name><surname>Garzon</surname><given-names>M</given-names></name><name><surname>Pisapia</surname><given-names>P</given-names></name><name><surname>Jordana-Ariza</surname><given-names>N</given-names></name><name><surname>Russo</surname><given-names>M</given-names></name><name><surname>Sgariglia</surname><given-names>R</given-names></name><name><surname>De Luca</surname><given-names>C</given-names></name><name><surname>Pepe</surname><given-names>F</given-names></name><etal/></person-group><article-title>Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients</article-title><source>Br J Cancer</source><year>2017</year><volume>116</volume><fpage>802</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">28170370</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><fpage>2472</fpage><lpage>2496</lpage><pub-id pub-id-type="pmid">25622259</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basnet</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>ZY</given-names></name><name><surname>Liao</surname><given-names>WQ</given-names></name><name><surname>Li</surname><given-names>SH</given-names></name><name><surname>Li</surname><given-names>PS</given-names></name><name><surname>Ge</surname><given-names>HY</given-names></name></person-group><article-title>The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis</article-title><source>J Cancer</source><year>2016</year><volume>7</volume><fpage>1105</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">27326254</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Messaoudi</surname><given-names>S</given-names></name><name><surname>Mouliere</surname><given-names>F</given-names></name><name><surname>Du Manoir</surname><given-names>S</given-names></name><name><surname>Bascoul-Mollevi</surname><given-names>C</given-names></name><name><surname>Gillet</surname><given-names>B</given-names></name><name><surname>Nouaille</surname><given-names>M</given-names></name><name><surname>Fiess</surname><given-names>C</given-names></name><name><surname>Crapez</surname><given-names>E</given-names></name><name><surname>Bibeau</surname><given-names>F</given-names></name><name><surname>Theillet</surname><given-names>C</given-names></name><etal/></person-group><article-title>Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><fpage>3067</fpage><lpage>3077</lpage><pub-id pub-id-type="pmid">26847055</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitahara</surname><given-names>M</given-names></name><name><surname>Hazama</surname><given-names>S</given-names></name><name><surname>Tsunedomi</surname><given-names>R</given-names></name><name><surname>Takenouchi</surname><given-names>H</given-names></name><name><surname>Kanekiyo</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Tomochika</surname><given-names>S</given-names></name><name><surname>Tokuhisa</surname><given-names>Y</given-names></name><name><surname>Iida</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer</article-title><source>Cancer Sci</source><year>2016</year><volume>107</volume><fpage>1825</fpage><lpage>1829</lpage><pub-id pub-id-type="pmid">27663862</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toledo</surname><given-names>RA</given-names></name><name><surname>Cubillo</surname><given-names>A</given-names></name><name><surname>Vega</surname><given-names>E</given-names></name><name><surname>Garralda</surname><given-names>E</given-names></name><name><surname>Alvarez</surname><given-names>R</given-names></name><name><surname>de la Varga</surname><given-names>LU</given-names></name><name><surname>Pascual</surname><given-names>JR</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>G</given-names></name><name><surname>Sarno</surname><given-names>F</given-names></name><name><surname>Prieto</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>35289</fpage><lpage>35300</lpage><pub-id pub-id-type="pmid">27852040</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeBlanc</surname><given-names>JG</given-names></name><name><surname>Milani</surname><given-names>C</given-names></name><name><surname>de Giori</surname><given-names>GS</given-names></name><name><surname>Sesma</surname><given-names>F</given-names></name><name><surname>van Sinderen</surname><given-names>D</given-names></name><name><surname>Ventura</surname><given-names>M</given-names></name></person-group><article-title>Bacteria as vitamin suppliers to their host: a gut microbiota perspective</article-title><source>Curr Opin Biotechnol</source><year>2013</year><volume>24</volume><fpage>160</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">22940212</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corr&#x000ea;a-Oliveira</surname><given-names>R</given-names></name><name><surname>Fachi</surname><given-names>JL</given-names></name><name><surname>Vieira</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>FT</given-names></name><name><surname>Vinolo</surname><given-names>MA</given-names></name></person-group><article-title>Regulation of immune cell function by short-chain fatty acids</article-title><source>Clin Transl Immunology</source><year>2016</year><volume>5</volume><fpage>e73</fpage><pub-id pub-id-type="pmid">27195116</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>DJ</given-names></name><name><surname>Preston</surname><given-names>T</given-names></name></person-group><article-title>Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism</article-title><source>Gut Microbes</source><year>2016</year><volume>7</volume><fpage>189</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">26963409</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natividad</surname><given-names>JM</given-names></name><name><surname>Verdu</surname><given-names>EF</given-names></name></person-group><article-title>Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications</article-title><source>Pharmacol Res</source><year>2013</year><volume>69</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">23089410</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>F</given-names></name><name><surname>B&#x000e4;ckhed</surname><given-names>F</given-names></name></person-group><article-title>The gut microbiota--masters of host development and physiology</article-title><source>Nat Rev Microbiol</source><year>2013</year><volume>11</volume><fpage>227</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">23435359</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Round</surname><given-names>JL</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>G</given-names></name><name><surname>Jabri</surname><given-names>B</given-names></name><name><surname>Chatila</surname><given-names>TA</given-names></name><name><surname>Mazmanian</surname><given-names>SK</given-names></name></person-group><article-title>The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota</article-title><source>Science</source><year>2011</year><volume>332</volume><fpage>974</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">21512004</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e4;umler</surname><given-names>AJ</given-names></name><name><surname>Sperandio</surname><given-names>V</given-names></name></person-group><article-title>Interactions between the microbiota and pathogenic bacteria in the gut</article-title><source>Nature</source><year>2016</year><volume>535</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">27383983</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Benno</surname><given-names>Y</given-names></name></person-group><article-title>Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods</article-title><source>Microbiol Immunol</source><year>2002</year><volume>46</volume><fpage>535</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">12363017</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Benno</surname><given-names>Y</given-names></name></person-group><article-title>Novel phylogenetic assignment database for terminal-restriction fragment length polymorphism analysis of human colonic microbiota</article-title><source>J Microbiol Methods</source><year>2005</year><volume>61</volume><fpage>305</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">15767007</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehingia</surname><given-names>M</given-names></name><name><surname>Devi</surname><given-names>KT</given-names></name><name><surname>Talukdar</surname><given-names>NC</given-names></name><name><surname>Talukdar</surname><given-names>R</given-names></name><name><surname>Reddy</surname><given-names>N</given-names></name><name><surname>Mande</surname><given-names>SS</given-names></name><name><surname>Deka</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>MR</given-names></name></person-group><article-title>Gut bacterial diversity of the tribes of India and comparison with the worldwide data</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>18563</fpage><pub-id pub-id-type="pmid">26689136</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagheddu</surname><given-names>V</given-names></name><name><surname>Patrone</surname><given-names>V</given-names></name><name><surname>Miragoli</surname><given-names>F</given-names></name><name><surname>Morelli</surname><given-names>L</given-names></name></person-group><article-title>Abundance and Diversity of Hydrogenotrophic Microorganisms in the Infant Gut before the Weaning Period Assessed by Denaturing Gradient Gel Electrophoresis and Quantitative PCR</article-title><source>Front Nutr</source><year>2017</year><volume>4</volume><fpage>29</fpage><pub-id pub-id-type="pmid">28695121</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swidsinski</surname><given-names>A</given-names></name><name><surname>D&#x000f6;rffel</surname><given-names>Y</given-names></name><name><surname>Loening-Baucke</surname><given-names>V</given-names></name><name><surname>Gille</surname><given-names>C</given-names></name><name><surname>Rei&#x000df;hauer</surname><given-names>A</given-names></name><name><surname>G&#x000f6;ktas</surname><given-names>O</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>M</given-names></name><name><surname>Neuhaus</surname><given-names>J</given-names></name><name><surname>Schr&#x000f6;dl</surname><given-names>W</given-names></name></person-group><article-title>Impact of humic acids on the colonic microbiome in healthy volunteers</article-title><source>World J Gastroenterol</source><year>2017</year><volume>23</volume><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">28223733</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balamurugan</surname><given-names>R</given-names></name><name><surname>Janardhan</surname><given-names>HP</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Chittaranjan</surname><given-names>SP</given-names></name><name><surname>Ramakrishna</surname><given-names>BS</given-names></name></person-group><article-title>Bacterial succession in the colon during childhood and adolescence: molecular studies in a southern Indian village</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>88</volume><fpage>1643</fpage><lpage>1647</lpage><pub-id pub-id-type="pmid">19064526</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobhani</surname><given-names>I</given-names></name><name><surname>Tap</surname><given-names>J</given-names></name><name><surname>Roudot-Thoraval</surname><given-names>F</given-names></name><name><surname>Roperch</surname><given-names>JP</given-names></name><name><surname>Letulle</surname><given-names>S</given-names></name><name><surname>Langella</surname><given-names>P</given-names></name><name><surname>Corthier</surname><given-names>G</given-names></name><name><surname>Tran Van Nhieu</surname><given-names>J</given-names></name><name><surname>Furet</surname><given-names>JP</given-names></name></person-group><article-title>Microbial dysbiosis in colorectal cancer (CRC) patients</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e16393</fpage><pub-id pub-id-type="pmid">21297998</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Jia</surname><given-names>H</given-names></name><name><surname>Stadlmayr</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Lan</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Jie</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gut microbiome development along the colorectal adenoma-carcinoma sequence</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>6528</fpage><pub-id pub-id-type="pmid">25758642</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Wong</surname><given-names>SH</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Liang</surname><given-names>QY</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Stenvang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>70</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">26408641</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amitay</surname><given-names>EL</given-names></name><name><surname>Werner</surname><given-names>S</given-names></name><name><surname>Vital</surname><given-names>M</given-names></name><name><surname>Pieper</surname><given-names>DH</given-names></name><name><surname>H&#x000f6;fler</surname><given-names>D</given-names></name><name><surname>Gierse</surname><given-names>IJ</given-names></name><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Balavarca</surname><given-names>Y</given-names></name><name><surname>Cuk</surname><given-names>K</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name></person-group><article-title>Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study</article-title><source>Carcinogenesis</source><year>2017</year><volume>38</volume><fpage>781</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">28582482</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>HM</given-names></name><name><surname>Campbell</surname><given-names>BJ</given-names></name><name><surname>Hart</surname><given-names>CA</given-names></name><name><surname>Mpofu</surname><given-names>C</given-names></name><name><surname>Nayar</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Englyst</surname><given-names>H</given-names></name><name><surname>Williams</surname><given-names>HF</given-names></name><name><surname>Rhodes</surname><given-names>JM</given-names></name></person-group><article-title>Enhanced Escherichia coli adherence and invasion in Crohn&#x02019;s disease and colon cancer</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>80</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">15236175</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdulamir</surname><given-names>AS</given-names></name><name><surname>Hafidh</surname><given-names>RR</given-names></name><name><surname>Bakar</surname><given-names>FA</given-names></name></person-group><article-title>Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis <italic>via</italic> IL-1, COX-2, and IL-8</article-title><source>Mol Cancer</source><year>2010</year><volume>9</volume><fpage>249</fpage><pub-id pub-id-type="pmid">20846456</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boleij</surname><given-names>A</given-names></name><name><surname>Hechenbleikner</surname><given-names>EM</given-names></name><name><surname>Goodwin</surname><given-names>AC</given-names></name><name><surname>Badani</surname><given-names>R</given-names></name><name><surname>Stein</surname><given-names>EM</given-names></name><name><surname>Lazarev</surname><given-names>MG</given-names></name><name><surname>Ellis</surname><given-names>B</given-names></name><name><surname>Carroll</surname><given-names>KC</given-names></name><name><surname>Albesiano</surname><given-names>E</given-names></name><name><surname>Wick</surname><given-names>EC</given-names></name><etal/></person-group><article-title>The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients</article-title><source>Clin Infect Dis</source><year>2015</year><volume>60</volume><fpage>208</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">25305284</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeller</surname><given-names>G</given-names></name><name><surname>Tap</surname><given-names>J</given-names></name><name><surname>Voigt</surname><given-names>AY</given-names></name><name><surname>Sunagawa</surname><given-names>S</given-names></name><name><surname>Kultima</surname><given-names>JR</given-names></name><name><surname>Costea</surname><given-names>PI</given-names></name><name><surname>Amiot</surname><given-names>A</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>J</given-names></name><name><surname>Brunetti</surname><given-names>F</given-names></name><name><surname>Habermann</surname><given-names>N</given-names></name><etal/></person-group><article-title>Potential of fecal microbiota for early-stage detection of colorectal cancer</article-title><source>Mol Syst Biol</source><year>2014</year><volume>10</volume><fpage>766</fpage><pub-id pub-id-type="pmid">25432777</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>MB</given-names></name><name><surname>Lynch</surname><given-names>J</given-names></name><name><surname>Starr</surname><given-names>TK</given-names></name><name><surname>Knights</surname><given-names>D</given-names></name><name><surname>Blekhman</surname><given-names>R</given-names></name></person-group><article-title>Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment</article-title><source>Genome Med</source><year>2015</year><volume>7</volume><fpage>55</fpage><pub-id pub-id-type="pmid">26170900</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arumugam</surname><given-names>M</given-names></name><name><surname>Raes</surname><given-names>J</given-names></name><name><surname>Pelletier</surname><given-names>E</given-names></name><name><surname>Le Paslier</surname><given-names>D</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Mende</surname><given-names>DR</given-names></name><name><surname>Fernandes</surname><given-names>GR</given-names></name><name><surname>Tap</surname><given-names>J</given-names></name><name><surname>Bruls</surname><given-names>T</given-names></name><name><surname>Batto</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Enterotypes of the human gut microbiome</article-title><source>Nature</source><year>2011</year><volume>473</volume><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">21508958</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mira-Pascual</surname><given-names>L</given-names></name><name><surname>Cabrera-Rubio</surname><given-names>R</given-names></name><name><surname>Ocon</surname><given-names>S</given-names></name><name><surname>Costales</surname><given-names>P</given-names></name><name><surname>Parra</surname><given-names>A</given-names></name><name><surname>Suarez</surname><given-names>A</given-names></name><name><surname>Moris</surname><given-names>F</given-names></name><name><surname>Rodrigo</surname><given-names>L</given-names></name><name><surname>Mira</surname><given-names>A</given-names></name><name><surname>Collado</surname><given-names>MC</given-names></name></person-group><article-title>Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers</article-title><source>J Gastroenterol</source><year>2015</year><volume>50</volume><fpage>167</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">24811328</pub-id></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Lou</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name></person-group><article-title>Mucosal adherent bacterial dysbiosis in patients with colorectal adenomas</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>26337</fpage><pub-id pub-id-type="pmid">27194068</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hibberd</surname><given-names>AA</given-names></name><name><surname>Lyra</surname><given-names>A</given-names></name><name><surname>Ouwehand</surname><given-names>AC</given-names></name><name><surname>Rolny</surname><given-names>P</given-names></name><name><surname>Lindegren</surname><given-names>H</given-names></name><name><surname>Cedg&#x000e5;rd</surname><given-names>L</given-names></name><name><surname>Wettergren</surname><given-names>Y</given-names></name></person-group><article-title>Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention</article-title><source>BMJ Open Gastroenterol</source><year>2017</year><volume>4</volume><fpage>e000145</fpage></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanapareddy</surname><given-names>N</given-names></name><name><surname>Legge</surname><given-names>RM</given-names></name><name><surname>Jovov</surname><given-names>B</given-names></name><name><surname>McCoy</surname><given-names>A</given-names></name><name><surname>Burcal</surname><given-names>L</given-names></name><name><surname>Araujo-Perez</surname><given-names>F</given-names></name><name><surname>Randall</surname><given-names>TA</given-names></name><name><surname>Galanko</surname><given-names>J</given-names></name><name><surname>Benson</surname><given-names>A</given-names></name><name><surname>Sandler</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans</article-title><source>ISME J</source><year>2012</year><volume>6</volume><fpage>1858</fpage><lpage>1868</lpage><pub-id pub-id-type="pmid">22622349</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>JJ</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Ravel</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fecal Microbiota Characteristics of Patients with Colorectal Adenoma Detected by Screening: A Population-based Study</article-title><source>EBioMedicine</source><year>2015</year><volume>2</volume><fpage>597</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">26288821</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>C</given-names></name><name><surname>Barnich</surname><given-names>N</given-names></name><name><surname>Nguyen</surname><given-names>HTT</given-names></name></person-group><article-title>Microbiota, Inflammation and Colorectal Cancer</article-title><source>Int J Mol Sci</source><year>2017</year><volume>18</volume><fpage>pii: E1310</fpage></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><collab>Zackular JP, Rogers MA, Ruffin MT 4th, Schloss PD</collab><article-title>The human gut microbiome as a screening tool for colorectal cancer</article-title><source>Cancer Prev Res (Phila)</source><year>2014</year><volume>7</volume><fpage>1112</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">25104642</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>JC</given-names></name><name><surname>Gharaibeh</surname><given-names>RZ</given-names></name><name><surname>M&#x000fc;hlbauer</surname><given-names>M</given-names></name><name><surname>Perez-Chanona</surname><given-names>E</given-names></name><name><surname>Uronis</surname><given-names>JM</given-names></name><name><surname>McCafferty</surname><given-names>J</given-names></name><name><surname>Fodor</surname><given-names>AA</given-names></name><name><surname>Jobin</surname><given-names>C</given-names></name></person-group><article-title>Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>4724</fpage><pub-id pub-id-type="pmid">25182170</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Pei</surname><given-names>Z</given-names></name><name><surname>Dominianni</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Goedert</surname><given-names>JJ</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>Human gut microbiome and risk for colorectal cancer</article-title><source>J Natl Cancer Inst</source><year>2013</year><volume>105</volume><fpage>1907</fpage><lpage>1911</lpage><pub-id pub-id-type="pmid">24316595</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ling</surname><given-names>Z</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>C</given-names></name></person-group><article-title>Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e39743</fpage><pub-id pub-id-type="pmid">22761885</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Dysbiosis signature of fecal microbiota in colorectal cancer patients</article-title><source>Microb Ecol</source><year>2013</year><volume>66</volume><fpage>462</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">23733170</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>M</given-names></name><name><surname>Buc</surname><given-names>E</given-names></name><name><surname>Sauvanet</surname><given-names>P</given-names></name><name><surname>Darcha</surname><given-names>C</given-names></name><name><surname>Dubois</surname><given-names>D</given-names></name><name><surname>Pereira</surname><given-names>B</given-names></name><name><surname>D&#x000e9;chelotte</surname><given-names>P</given-names></name><name><surname>Bonnet</surname><given-names>R</given-names></name><name><surname>Pezet</surname><given-names>D</given-names></name><name><surname>Darfeuille-Michaud</surname><given-names>A</given-names></name></person-group><article-title>Colonization of the human gut by E. coli and colorectal cancer risk</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>859</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">24334760</pub-id></element-citation></ref><ref id="B146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>JC</given-names></name><name><surname>Perez-Chanona</surname><given-names>E</given-names></name><name><surname>M&#x000fc;hlbauer</surname><given-names>M</given-names></name><name><surname>Tomkovich</surname><given-names>S</given-names></name><name><surname>Uronis</surname><given-names>JM</given-names></name><name><surname>Fan</surname><given-names>TJ</given-names></name><name><surname>Campbell</surname><given-names>BJ</given-names></name><name><surname>Abujamel</surname><given-names>T</given-names></name><name><surname>Dogan</surname><given-names>B</given-names></name><name><surname>Rogers</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Intestinal inflammation targets cancer-inducing activity of the microbiota</article-title><source>Science</source><year>2012</year><volume>338</volume><fpage>120</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">22903521</pub-id></element-citation></ref><ref id="B147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostic</surname><given-names>AD</given-names></name><name><surname>Gevers</surname><given-names>D</given-names></name><name><surname>Pedamallu</surname><given-names>CS</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Duke</surname><given-names>F</given-names></name><name><surname>Earl</surname><given-names>AM</given-names></name><name><surname>Ojesina</surname><given-names>AI</given-names></name><name><surname>Jung</surname><given-names>J</given-names></name><name><surname>Bass</surname><given-names>AJ</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genomic analysis identifies association of Fusobacterium with colorectal carcinoma</article-title><source>Genome Res</source><year>2012</year><volume>22</volume><fpage>292</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">22009990</pub-id></element-citation></ref><ref id="B148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchesi</surname><given-names>JR</given-names></name><name><surname>Dutilh</surname><given-names>BE</given-names></name><name><surname>Hall</surname><given-names>N</given-names></name><name><surname>Peters</surname><given-names>WH</given-names></name><name><surname>Roelofs</surname><given-names>R</given-names></name><name><surname>Boleij</surname><given-names>A</given-names></name><name><surname>Tjalsma</surname><given-names>H</given-names></name></person-group><article-title>Towards the human colorectal cancer microbiome</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e20447</fpage><pub-id pub-id-type="pmid">21647227</pub-id></element-citation></ref><ref id="B149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viljoen</surname><given-names>KS</given-names></name><name><surname>Dakshinamurthy</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>P</given-names></name><name><surname>Blackburn</surname><given-names>JM</given-names></name></person-group><article-title>Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0119462</fpage><pub-id pub-id-type="pmid">25751261</pub-id></element-citation></ref><ref id="B150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>JI</given-names></name><name><surname>Aitchison</surname><given-names>A</given-names></name><name><surname>Purcell</surname><given-names>RV</given-names></name><name><surname>Greenlees</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>JF</given-names></name><name><surname>Frizelle</surname><given-names>FA</given-names></name></person-group><article-title>Screening for enterotoxigenic Bacteroides fragilis in stool samples</article-title><source>Anaerobe</source><year>2016</year><volume>40</volume><fpage>50</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">27166180</pub-id></element-citation></ref><ref id="B151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekl&#x000f6;f</surname><given-names>V</given-names></name><name><surname>L&#x000f6;fgren-Burstr&#x000f6;m</surname><given-names>A</given-names></name><name><surname>Zingmark</surname><given-names>C</given-names></name><name><surname>Edin</surname><given-names>S</given-names></name><name><surname>Larsson</surname><given-names>P</given-names></name><name><surname>Karling</surname><given-names>P</given-names></name><name><surname>Alexeyev</surname><given-names>O</given-names></name><name><surname>Ruteg&#x000e5;rd</surname><given-names>J</given-names></name><name><surname>Wikberg</surname><given-names>ML</given-names></name><name><surname>Palmqvist</surname><given-names>R</given-names></name></person-group><article-title>Cancer-associated fecal microbial markers in colorectal cancer detection</article-title><source>Int J Cancer</source><year>2017</year><volume>141</volume><fpage>2528</fpage><lpage>2536</lpage><pub-id pub-id-type="pmid">28833079</pub-id></element-citation></ref><ref id="B152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prorok-Hamon</surname><given-names>M</given-names></name><name><surname>Friswell</surname><given-names>MK</given-names></name><name><surname>Alswied</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>CL</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Flanagan</surname><given-names>PK</given-names></name><name><surname>Knight</surname><given-names>P</given-names></name><name><surname>Codling</surname><given-names>C</given-names></name><name><surname>Marchesi</surname><given-names>JR</given-names></name><name><surname>Winstanley</surname><given-names>C</given-names></name><etal/></person-group><article-title>Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer</article-title><source>Gut</source><year>2014</year><volume>63</volume><fpage>761</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">23846483</pub-id></element-citation></ref><ref id="B153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakatsu</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>SH</given-names></name><name><surname>Wu</surname><given-names>WK</given-names></name><name><surname>Ng</surname><given-names>SC</given-names></name><name><surname>Tsoi</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><etal/></person-group><article-title>Gut mucosal microbiome across stages of colorectal carcinogenesis</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>8727</fpage><pub-id pub-id-type="pmid">26515465</pub-id></element-citation></ref><ref id="B154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejea</surname><given-names>CM</given-names></name><name><surname>Fathi</surname><given-names>P</given-names></name><name><surname>Craig</surname><given-names>JM</given-names></name><name><surname>Boleij</surname><given-names>A</given-names></name><name><surname>Taddese</surname><given-names>R</given-names></name><name><surname>Geis</surname><given-names>AL</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>DeStefano Shields</surname><given-names>CE</given-names></name><name><surname>Hechenbleikner</surname><given-names>EM</given-names></name><name><surname>Huso</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">29420293</pub-id></element-citation></ref><ref id="B155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flemer</surname><given-names>B</given-names></name><name><surname>Lynch</surname><given-names>DB</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Jeffery</surname><given-names>IB</given-names></name><name><surname>Ryan</surname><given-names>FJ</given-names></name><name><surname>Claesson</surname><given-names>MJ</given-names></name><name><surname>O&#x02019;Riordain</surname><given-names>M</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name><name><surname>O&#x02019;Toole</surname><given-names>PW</given-names></name></person-group><article-title>Tumour-associated and non-tumour-associated microbiota in colorectal cancer</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>633</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">26992426</pub-id></element-citation></ref><ref id="B156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>ML</given-names></name><name><surname>Liguori</surname><given-names>G</given-names></name><name><surname>Lamas</surname><given-names>B</given-names></name><name><surname>Brandi</surname><given-names>G</given-names></name><name><surname>da Costa</surname><given-names>G</given-names></name><name><surname>Hoffmann</surname><given-names>TW</given-names></name><name><surname>Pierluigi Di Simone</surname><given-names>M</given-names></name><name><surname>Calabrese</surname><given-names>C</given-names></name><name><surname>Poggioli</surname><given-names>G</given-names></name><name><surname>Langella</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mucosa-associated microbiota dysbiosis in colitis associated cancer</article-title><source>Gut Microbes</source><year>2017</year><comment>Epub ahead of print</comment></element-citation></ref><ref id="B157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagni&#x000e8;re</surname><given-names>J</given-names></name><name><surname>Bonnin</surname><given-names>V</given-names></name><name><surname>Jarrousse</surname><given-names>AS</given-names></name><name><surname>Cardamone</surname><given-names>E</given-names></name><name><surname>Agus</surname><given-names>A</given-names></name><name><surname>Uhrhammer</surname><given-names>N</given-names></name><name><surname>Sauvanet</surname><given-names>P</given-names></name><name><surname>D&#x000e9;chelotte</surname><given-names>P</given-names></name><name><surname>Barnich</surname><given-names>N</given-names></name><name><surname>Bonnet</surname><given-names>R</given-names></name><etal/></person-group><article-title>Interactions between microsatellite instability and human gut colonization by <italic>Escherichia coli</italic> in colorectal cancer</article-title><source>Clin Sci (Lond)</source><year>2017</year><volume>131</volume><fpage>471</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">28093453</pub-id></element-citation></ref><ref id="B158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mima</surname><given-names>K</given-names></name><name><surname>Nishihara</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>ZR</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Sukawa</surname><given-names>Y</given-names></name><name><surname>Nowak</surname><given-names>JA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Dou</surname><given-names>R</given-names></name><name><surname>Masugi</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis</article-title><source>Gut</source><year>2016</year><volume>65</volume><fpage>1973</fpage><lpage>1980</lpage><pub-id pub-id-type="pmid">26311717</pub-id></element-citation></ref><ref id="B159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>DS</given-names></name></person-group><article-title>Current progress in computational metabolomics</article-title><source>Brief Bioinform</source><year>2007</year><volume>8</volume><fpage>279</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">17626065</pub-id></element-citation></ref><ref id="B160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>ID</given-names></name><name><surname>Nicholson</surname><given-names>JK</given-names></name></person-group><article-title>Metabolic phenotyping in health and disease</article-title><source>Cell</source><year>2008</year><volume>134</volume><fpage>714</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">18775301</pub-id></element-citation></ref><ref id="B161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>E</given-names></name><name><surname>Loo</surname><given-names>RL</given-names></name><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Bictash</surname><given-names>M</given-names></name><name><surname>Yap</surname><given-names>IK</given-names></name><name><surname>Chan</surname><given-names>Q</given-names></name><name><surname>Ebbels</surname><given-names>T</given-names></name><name><surname>De Iorio</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>IJ</given-names></name><name><surname>Veselkov</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Human metabolic phenotype diversity and its association with diet and blood pressure</article-title><source>Nature</source><year>2008</year><volume>453</volume><fpage>396</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">18425110</pub-id></element-citation></ref><ref id="B162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname><given-names>ME</given-names></name><name><surname>Maibaum</surname><given-names>EC</given-names></name><name><surname>Teague</surname><given-names>C</given-names></name><name><surname>Ueshima</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Lindon</surname><given-names>JC</given-names></name><name><surname>Nicholson</surname><given-names>JK</given-names></name><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study</article-title><source>Anal Chem</source><year>2006</year><volume>78</volume><fpage>2199</fpage><lpage>2208</lpage><pub-id pub-id-type="pmid">16579598</pub-id></element-citation></ref><ref id="B163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>EG</given-names></name><name><surname>Barbas</surname><given-names>C</given-names></name></person-group><article-title>Metabolomics in cancer biomarker discovery: current trends and future perspectives</article-title><source>J Pharm Biomed Anal</source><year>2014</year><volume>87</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">24091079</pub-id></element-citation></ref><ref id="B164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>EC</given-names></name><name><surname>Koh</surname><given-names>PK</given-names></name><name><surname>Mal</surname><given-names>M</given-names></name><name><surname>Cheah</surname><given-names>PY</given-names></name><name><surname>Eu</surname><given-names>KW</given-names></name><name><surname>Backshall</surname><given-names>A</given-names></name><name><surname>Cavill</surname><given-names>R</given-names></name><name><surname>Nicholson</surname><given-names>JK</given-names></name><name><surname>Keun</surname><given-names>HC</given-names></name></person-group><article-title>Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS)</article-title><source>J Proteome Res</source><year>2009</year><volume>8</volume><fpage>352</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">19063642</pub-id></element-citation></ref><ref id="B165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>DG</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Weir</surname><given-names>TL</given-names></name><name><surname>O&#x02019;Malia</surname><given-names>J</given-names></name><name><surname>Bazan</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>RJ</given-names></name><name><surname>Ryan</surname><given-names>EP</given-names></name></person-group><article-title>Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool</article-title><source>Cancer Metab</source><year>2016</year><volume>4</volume><fpage>11</fpage><pub-id pub-id-type="pmid">27275383</pub-id></element-citation></ref><ref id="B166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farshidfar</surname><given-names>F</given-names></name><name><surname>Weljie</surname><given-names>AM</given-names></name><name><surname>Kopciuk</surname><given-names>KA</given-names></name><name><surname>Hilsden</surname><given-names>R</given-names></name><name><surname>McGregor</surname><given-names>SE</given-names></name><name><surname>Buie</surname><given-names>WD</given-names></name><name><surname>MacLean</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name><name><surname>Bathe</surname><given-names>OF</given-names></name></person-group><article-title>A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics</article-title><source>Br J Cancer</source><year>2016</year><volume>115</volume><fpage>848</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">27560555</pub-id></element-citation></ref><ref id="B167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farshidfar</surname><given-names>F</given-names></name><name><surname>Kopciuk</surname><given-names>KA</given-names></name><name><surname>Hilsden</surname><given-names>R</given-names></name><name><surname>McGregor</surname><given-names>SE</given-names></name><name><surname>Mazurak</surname><given-names>VC</given-names></name><name><surname>Buie</surname><given-names>WD</given-names></name><name><surname>MacLean</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name><name><surname>Bathe</surname><given-names>OF</given-names></name></person-group><article-title>A quantitative multimodal metabolomic assay for colorectal cancer</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><fpage>26</fpage><pub-id pub-id-type="pmid">29301511</pub-id></element-citation></ref><ref id="B168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchiyama</surname><given-names>K</given-names></name><name><surname>Yagi</surname><given-names>N</given-names></name><name><surname>Mizushima</surname><given-names>K</given-names></name><name><surname>Higashimura</surname><given-names>Y</given-names></name><name><surname>Hirai</surname><given-names>Y</given-names></name><name><surname>Okayama</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Katada</surname><given-names>K</given-names></name><name><surname>Kamada</surname><given-names>K</given-names></name><name><surname>Handa</surname><given-names>O</given-names></name><etal/></person-group><article-title>Serum metabolomics analysis for early detection of colorectal cancer</article-title><source>J Gastroenterol</source><year>2017</year><volume>52</volume><fpage>677</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">27650200</pub-id></element-citation></ref><ref id="B169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mal</surname><given-names>M</given-names></name></person-group><article-title>Noninvasive metabolic profiling for painless diagnosis of human diseases and disorders</article-title><source>Future Sci OA</source><year>2016</year><volume>2</volume><fpage>FSO106</fpage><pub-id pub-id-type="pmid">28031956</pub-id></element-citation></ref><ref id="B170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Keefe</surname><given-names>SJ</given-names></name></person-group><article-title>Diet, microorganisms and their metabolites, and colon cancer</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2016</year><volume>13</volume><fpage>691</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">27848961</pub-id></element-citation></ref><ref id="B171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flint</surname><given-names>HJ</given-names></name><name><surname>Scott</surname><given-names>KP</given-names></name><name><surname>Louis</surname><given-names>P</given-names></name><name><surname>Duncan</surname><given-names>SH</given-names></name></person-group><article-title>The role of the gut microbiota in nutrition and health</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2012</year><volume>9</volume><fpage>577</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">22945443</pub-id></element-citation></ref><ref id="B172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>I</given-names></name><name><surname>Gibson</surname><given-names>G</given-names></name><name><surname>Heinken</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>K</given-names></name><name><surname>Swann</surname><given-names>J</given-names></name><name><surname>Thiele</surname><given-names>I</given-names></name><name><surname>Tuohy</surname><given-names>K</given-names></name></person-group><article-title>Gut microbiota functions: metabolism of nutrients and other food components</article-title><source>Eur J Nutr</source><year>2018</year><volume>57</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">28393285</pub-id></element-citation></ref><ref id="B173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouwehand</surname><given-names>AC</given-names></name><name><surname>Derrien</surname><given-names>M</given-names></name><name><surname>de Vos</surname><given-names>W</given-names></name><name><surname>Tiihonen</surname><given-names>K</given-names></name><name><surname>Rautonen</surname><given-names>N</given-names></name></person-group><article-title>Prebiotics and other microbial substrates for gut functionality</article-title><source>Curr Opin Biotechnol</source><year>2005</year><volume>16</volume><fpage>212</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">15831389</pub-id></element-citation></ref><ref id="B174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>TL</given-names></name><name><surname>Wolin</surname><given-names>MJ</given-names></name></person-group><article-title>Pathways of acetate, propionate, and butyrate formation by the human fecal microbial flora</article-title><source>Appl Environ Microbiol</source><year>1996</year><volume>62</volume><fpage>1589</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">8633856</pub-id></element-citation></ref><ref id="B175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Beek</surname><given-names>CM</given-names></name><name><surname>Dejong</surname><given-names>CHC</given-names></name><name><surname>Troost</surname><given-names>FJ</given-names></name><name><surname>Masclee</surname><given-names>AAM</given-names></name><name><surname>Lenaerts</surname><given-names>K</given-names></name></person-group><article-title>Role of short-chain fatty acids in colonic inflammation, carcinogenesis, and mucosal protection and healing</article-title><source>Nutr Rev</source><year>2017</year><volume>75</volume><fpage>286</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">28402523</pub-id></element-citation></ref><ref id="B176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrasa</surname><given-names>JI</given-names></name><name><surname>Olmo</surname><given-names>N</given-names></name><name><surname>Lizarbe</surname><given-names>MA</given-names></name><name><surname>Turnay</surname><given-names>J</given-names></name></person-group><article-title>Bile acids in the colon, from healthy to cytotoxic molecules</article-title><source>Toxicol In Vitro</source><year>2013</year><volume>27</volume><fpage>964</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">23274766</pub-id></element-citation></ref><ref id="B177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridlon</surname><given-names>JM</given-names></name><name><surname>Kang</surname><given-names>DJ</given-names></name><name><surname>Hylemon</surname><given-names>PB</given-names></name></person-group><article-title>Bile salt biotransformations by human intestinal bacteria</article-title><source>J Lipid Res</source><year>2006</year><volume>47</volume><fpage>241</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">16299351</pub-id></element-citation></ref><ref id="B178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>BV</given-names></name><name><surname>Begley</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>C</given-names></name><name><surname>Gahan</surname><given-names>CG</given-names></name><name><surname>Marchesi</surname><given-names>JR</given-names></name></person-group><article-title>Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>13580</fpage><lpage>13585</lpage><pub-id pub-id-type="pmid">18757757</pub-id></element-citation></ref><ref id="B179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocvirk</surname><given-names>S</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>SJ</given-names></name></person-group><article-title>Influence of Bile Acids on Colorectal Cancer Risk: Potential Mechanisms Mediated by Diet - Gut Microbiota Interactions</article-title><source>Curr Nutr Rep</source><year>2017</year><volume>6</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">29430336</pub-id></element-citation></ref><ref id="B180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manach</surname><given-names>C</given-names></name><name><surname>Scalbert</surname><given-names>A</given-names></name><name><surname>Morand</surname><given-names>C</given-names></name><name><surname>R&#x000e9;m&#x000e9;sy</surname><given-names>C</given-names></name><name><surname>Jim&#x000e9;nez</surname><given-names>L</given-names></name></person-group><article-title>Polyphenols: food sources and bioavailability</article-title><source>Am J Clin Nutr</source><year>2004</year><volume>79</volume><fpage>727</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">15113710</pub-id></element-citation></ref><ref id="B181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mar&#x000ed;n</surname><given-names>L</given-names></name><name><surname>Migu&#x000e9;lez</surname><given-names>EM</given-names></name><name><surname>Villar</surname><given-names>CJ</given-names></name><name><surname>Lomb&#x000f3;</surname><given-names>F</given-names></name></person-group><article-title>Bioavailability of dietary polyphenols and gut microbiota metabolism: antimicrobial properties</article-title><source>Biomed Res Int</source><year>2015</year><volume>2015</volume><fpage>905215</fpage><pub-id pub-id-type="pmid">25802870</pub-id></element-citation></ref><ref id="B182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>W</given-names></name><name><surname>Duthie</surname><given-names>G</given-names></name></person-group><article-title>Plant secondary metabolites and gut health: the case for phenolic acids</article-title><source>Proc Nutr Soc</source><year>2011</year><volume>70</volume><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">21781364</pub-id></element-citation></ref><ref id="B183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardona</surname><given-names>F</given-names></name><name><surname>Andr&#x000e9;s-Lacueva</surname><given-names>C</given-names></name><name><surname>Tulipani</surname><given-names>S</given-names></name><name><surname>Tinahones</surname><given-names>FJ</given-names></name><name><surname>Queipo-Ortu&#x000f1;o</surname><given-names>MI</given-names></name></person-group><article-title>Benefits of polyphenols on gut microbiota and implications in human health</article-title><source>J Nutr Biochem</source><year>2013</year><volume>24</volume><fpage>1415</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">23849454</pub-id></element-citation></ref><ref id="B184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>WR</given-names></name><name><surname>Duncan</surname><given-names>SH</given-names></name><name><surname>Scobbie</surname><given-names>L</given-names></name><name><surname>Duncan</surname><given-names>G</given-names></name><name><surname>Cantlay</surname><given-names>L</given-names></name><name><surname>Calder</surname><given-names>AG</given-names></name><name><surname>Anderson</surname><given-names>SE</given-names></name><name><surname>Flint</surname><given-names>HJ</given-names></name></person-group><article-title>Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein</article-title><source>Mol Nutr Food Res</source><year>2013</year><volume>57</volume><fpage>523</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">23349065</pub-id></element-citation></ref><ref id="B185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>YH</given-names></name><name><surname>Jakszyn</surname><given-names>P</given-names></name><name><surname>Luben</surname><given-names>RN</given-names></name><name><surname>Mulligan</surname><given-names>AA</given-names></name><name><surname>Mitrou</surname><given-names>PN</given-names></name><name><surname>Khaw</surname><given-names>KT</given-names></name></person-group><article-title>N-Nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Study</article-title><source>Am J Clin Nutr</source><year>2011</year><volume>93</volume><fpage>1053</fpage><lpage>1061</lpage><pub-id pub-id-type="pmid">21430112</pub-id></element-citation></ref><ref id="B186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>CI</given-names></name><name><surname>Rowland</surname><given-names>IR</given-names></name></person-group><article-title>Diet and cancer: assessing the risk</article-title><source>Br J Nutr</source><year>2002</year><volume>88 Suppl 1</volume><fpage>S73</fpage><lpage>S87</lpage><pub-id pub-id-type="pmid">12215186</pub-id></element-citation></ref><ref id="B187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roediger</surname><given-names>WE</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name><name><surname>Babidge</surname><given-names>W</given-names></name></person-group><article-title>Colonic sulfide in pathogenesis and treatment of ulcerative colitis</article-title><source>Dig Dis Sci</source><year>1997</year><volume>42</volume><fpage>1571</fpage><lpage>1579</lpage><pub-id pub-id-type="pmid">9286219</pub-id></element-citation></ref><ref id="B188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homann</surname><given-names>N</given-names></name></person-group><article-title>Alcohol and upper gastrointestinal tract cancer: the role of local acetaldehyde production</article-title><source>Addict Biol</source><year>2001</year><volume>6</volume><fpage>309</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">11900609</pub-id></element-citation></ref><ref id="B189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>CH</given-names></name><name><surname>Dejea</surname><given-names>CM</given-names></name><name><surname>Edler</surname><given-names>D</given-names></name><name><surname>Hoang</surname><given-names>LT</given-names></name><name><surname>Santidrian</surname><given-names>AF</given-names></name><name><surname>Felding</surname><given-names>BH</given-names></name><name><surname>Ivanisevic</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>K</given-names></name><name><surname>Wick</surname><given-names>EC</given-names></name><name><surname>Hechenbleikner</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Metabolism links bacterial biofilms and colon carcinogenesis</article-title><source>Cell Metab</source><year>2015</year><volume>21</volume><fpage>891</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">25959674</pub-id></element-citation></ref><ref id="B190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JH</given-names></name><name><surname>Macfarlane</surname><given-names>GT</given-names></name></person-group><article-title>The control and consequences of bacterial fermentation in the human colon</article-title><source>J Appl Bacteriol</source><year>1991</year><volume>70</volume><fpage>443</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">1938669</pub-id></element-citation></ref><ref id="B191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suarez</surname><given-names>F</given-names></name><name><surname>Furne</surname><given-names>J</given-names></name><name><surname>Springfield</surname><given-names>J</given-names></name><name><surname>Levitt</surname><given-names>M</given-names></name></person-group><article-title>Insights into human colonic physiology obtained from the study of flatus composition</article-title><source>Am J Physiol</source><year>1997</year><volume>272</volume><fpage>G1028</fpage><lpage>G1033</lpage><pub-id pub-id-type="pmid">9176210</pub-id></element-citation></ref><ref id="B192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>MD</given-names></name><name><surname>Xian</surname><given-names>L</given-names></name><name><surname>Huso</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>JJ</given-names></name><name><surname>Huso</surname><given-names>D</given-names></name><name><surname>Cope</surname><given-names>LM</given-names></name><name><surname>Gang</surname><given-names>DR</given-names></name><name><surname>Siems</surname><given-names>WF</given-names></name><name><surname>Resar</surname><given-names>L</given-names></name><name><surname>Reeves</surname><given-names>R</given-names></name><etal/></person-group><article-title>Fecal Metabolome in Hmga1 Transgenic Mice with Polyposis: Evidence for Potential Screen for Early Detection of Precursor Lesions in Colorectal Cancer</article-title><source>J Proteome Res</source><year>2016</year><volume>15</volume><fpage>4176</fpage><lpage>4187</lpage><pub-id pub-id-type="pmid">27696867</pub-id></element-citation></ref><ref id="B193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>TL</given-names></name><name><surname>Manter</surname><given-names>DK</given-names></name><name><surname>Sheflin</surname><given-names>AM</given-names></name><name><surname>Barnett</surname><given-names>BA</given-names></name><name><surname>Heuberger</surname><given-names>AL</given-names></name><name><surname>Ryan</surname><given-names>EP</given-names></name></person-group><article-title>Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e70803</fpage><pub-id pub-id-type="pmid">23940645</pub-id></element-citation></ref><ref id="B194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>GA</given-names></name><name><surname>Krause</surname><given-names>JA</given-names></name><name><surname>Miller</surname><given-names>TL</given-names></name><name><surname>Wolin</surname><given-names>MJ</given-names></name></person-group><article-title>Short chain fatty acid distributions of enema samples from a sigmoidoscopy population: an association of high acetate and low butyrate ratios with adenomatous polyps and colon cancer</article-title><source>Gut</source><year>1988</year><volume>29</volume><fpage>1539</fpage><lpage>1543</lpage><pub-id pub-id-type="pmid">3209110</pub-id></element-citation></ref><ref id="B195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Jin</surname><given-names>YH</given-names></name></person-group><article-title>Intestinal bacterial beta-glucuronidase activity of patients with colon cancer</article-title><source>Arch Pharm Res</source><year>2001</year><volume>24</volume><fpage>564</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">11794536</pub-id></element-citation></ref><ref id="B196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>DeLany</surname><given-names>JP</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>SJ</given-names></name></person-group><article-title>Association between low colonic short-chain fatty acids and high bile acids in high colon cancer risk populations</article-title><source>Nutr Cancer</source><year>2012</year><volume>64</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">22136517</pub-id></element-citation></ref><ref id="B197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimoto</surname><given-names>S</given-names></name><name><surname>Loo</surname><given-names>TM</given-names></name><name><surname>Atarashi</surname><given-names>K</given-names></name><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Oyadomari</surname><given-names>S</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Oshima</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><etal/></person-group><article-title>Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome</article-title><source>Nature</source><year>2013</year><volume>499</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">23803760</pub-id></element-citation></ref><ref id="B198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roisin Hughes</surname><given-names>IR</given-names></name></person-group><article-title>Metabolic Activities of the Gut Microflora in Relation to Cancer</article-title><source>Microb Ecol Health Dis</source><year>2000</year><volume>12</volume><fpage>179</fpage><lpage>185</lpage></element-citation></ref><ref id="B199"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbonero</surname><given-names>F</given-names></name><name><surname>Benefiel</surname><given-names>AC</given-names></name><name><surname>Gaskins</surname><given-names>HR</given-names></name></person-group><article-title>Contributions of the microbial hydrogen economy to colonic homeostasis</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2012</year><volume>9</volume><fpage>504</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">22585131</pub-id></element-citation></ref><ref id="B200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>JY</given-names></name></person-group><article-title>Systematic evaluation of supervised classifiers for fecal microbiota-based prediction of colorectal cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>9546</fpage><lpage>9556</lpage><pub-id pub-id-type="pmid">28061434</pub-id></element-citation></ref><ref id="B201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>MS</given-names></name><name><surname>DeSantis</surname><given-names>TZ</given-names></name><name><surname>Weinmaier</surname><given-names>T</given-names></name><name><surname>McMurdie</surname><given-names>PJ</given-names></name><name><surname>Cope</surname><given-names>JL</given-names></name><name><surname>Altrichter</surname><given-names>A</given-names></name><name><surname>Yamal</surname><given-names>JM</given-names></name><name><surname>Hollister</surname><given-names>EB</given-names></name></person-group><article-title>Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer</article-title><source>Gut</source><year>2018</year><volume>67</volume><fpage>882</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">28341746</pub-id></element-citation></ref><ref id="B202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amitay</surname><given-names>EL</given-names></name><name><surname>Krilaviciute</surname><given-names>A</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name></person-group><article-title>Systematic review: Gut microbiota in fecal samples and detection of colorectal neoplasms</article-title><source>Gut Microbes</source><year>2018</year><fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="B203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients&#x02019; survival? A pilot study on relevant mechanism</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>46158</fpage><lpage>46172</lpage><pub-id pub-id-type="pmid">27323816</pub-id></element-citation></ref><ref id="B204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SH</given-names></name><name><surname>Kwong</surname><given-names>TNY</given-names></name><name><surname>Chow</surname><given-names>TC</given-names></name><name><surname>Luk</surname><given-names>AKC</given-names></name><name><surname>Dai</surname><given-names>RZW</given-names></name><name><surname>Nakatsu</surname><given-names>G</given-names></name><name><surname>Lam</surname><given-names>TYT</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>JCY</given-names></name><name><surname>Chan</surname><given-names>FKL</given-names></name><etal/></person-group><article-title>Quantitation of faecal <italic>Fusobacterium</italic> improves faecal immunochemical test in detecting advanced colorectal neoplasia</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>1441</fpage><lpage>1448</lpage><pub-id pub-id-type="pmid">27797940</pub-id></element-citation></ref><ref id="B205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezabeh</surname><given-names>T</given-names></name><name><surname>Somorjai</surname><given-names>R</given-names></name><name><surname>Dolenko</surname><given-names>B</given-names></name><name><surname>Bryskina</surname><given-names>N</given-names></name><name><surname>Levin</surname><given-names>B</given-names></name><name><surname>Bernstein</surname><given-names>CN</given-names></name><name><surname>Jeyarajah</surname><given-names>E</given-names></name><name><surname>Steinhart</surname><given-names>AH</given-names></name><name><surname>Rubin</surname><given-names>DT</given-names></name><name><surname>Smith</surname><given-names>IC</given-names></name></person-group><article-title>Detecting colorectal cancer by 1H magnetic resonance spectroscopy of fecal extracts</article-title><source>NMR Biomed</source><year>2009</year><volume>22</volume><fpage>593</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">19259992</pub-id></element-citation></ref><ref id="B206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monle&#x000f3;n</surname><given-names>D</given-names></name><name><surname>Morales</surname><given-names>JM</given-names></name><name><surname>Barrasa</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>JA</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>C</given-names></name><name><surname>Celda</surname><given-names>B</given-names></name></person-group><article-title>Metabolite profiling of fecal water extracts from human colorectal cancer</article-title><source>NMR Biomed</source><year>2009</year><volume>22</volume><fpage>342</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">19006102</pub-id></element-citation></ref><ref id="B207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>JJ</given-names></name><name><surname>Sampson</surname><given-names>JN</given-names></name><name><surname>Moore</surname><given-names>SC</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name></person-group><article-title>Fecal metabolomics: assay performance and association with colorectal cancer</article-title><source>Carcinogenesis</source><year>2014</year><volume>35</volume><fpage>2089</fpage><lpage>2096</lpage><pub-id pub-id-type="pmid">25037050</pub-id></element-citation></ref><ref id="B208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phua</surname><given-names>LC</given-names></name><name><surname>Chue</surname><given-names>XP</given-names></name><name><surname>Koh</surname><given-names>PK</given-names></name><name><surname>Cheah</surname><given-names>PY</given-names></name><name><surname>Ho</surname><given-names>HK</given-names></name><name><surname>Chan</surname><given-names>EC</given-names></name></person-group><article-title>Non-invasive fecal metabonomic detection of colorectal cancer</article-title><source>Cancer Biol Ther</source><year>2014</year><volume>15</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">24424155</pub-id></element-citation></ref><ref id="B209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Meij</surname><given-names>TG</given-names></name><name><surname>Larbi</surname><given-names>IB</given-names></name><name><surname>van der Schee</surname><given-names>MP</given-names></name><name><surname>Lentferink</surname><given-names>YE</given-names></name><name><surname>Paff</surname><given-names>T</given-names></name><name><surname>Terhaar Sive Droste</surname><given-names>JS</given-names></name><name><surname>Mulder</surname><given-names>CJ</given-names></name><name><surname>van Bodegraven</surname><given-names>AA</given-names></name><name><surname>de Boer</surname><given-names>NK</given-names></name></person-group><article-title>Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study</article-title><source>Int J Cancer</source><year>2014</year><volume>134</volume><fpage>1132</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">23959518</pub-id></element-citation></ref><ref id="B210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batty</surname><given-names>CA</given-names></name><name><surname>Cauchi</surname><given-names>M</given-names></name><name><surname>Louren&#x000e7;o</surname><given-names>C</given-names></name><name><surname>Hunter</surname><given-names>JO</given-names></name><name><surname>Turner</surname><given-names>C</given-names></name></person-group><article-title>Use of the Analysis of the Volatile Faecal Metabolome in Screening for Colorectal Cancer</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0130301</fpage><pub-id pub-id-type="pmid">26086914</pub-id></element-citation></ref><ref id="B211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Sampson</surname><given-names>JN</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Goedert</surname><given-names>JJ</given-names></name></person-group><article-title>Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0152126</fpage><pub-id pub-id-type="pmid">27015276</pub-id></element-citation></ref><ref id="B212"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronckaers</surname><given-names>A</given-names></name><name><surname>Balzarini</surname><given-names>J</given-names></name><name><surname>Liekens</surname><given-names>S</given-names></name></person-group><article-title>The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy</article-title><source>Biochem Pharmacol</source><year>2008</year><volume>76</volume><fpage>188</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">18555978</pub-id></element-citation></ref><ref id="B213"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esp&#x000ed;n</surname><given-names>JC</given-names></name><name><surname>Gonz&#x000e1;lez-Sarr&#x000ed;as</surname><given-names>A</given-names></name><name><surname>Tom&#x000e1;s-Barber&#x000e1;n</surname><given-names>FA</given-names></name></person-group><article-title>The gut microbiota: A key factor in the therapeutic effects of (poly)phenols</article-title><source>Biochem Pharmacol</source><year>2017</year><volume>139</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">28483461</pub-id></element-citation></ref><ref id="B214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guthrie</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Daily</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>L</given-names></name></person-group><article-title>Human microbiome signatures of differential colorectal cancer drug metabolism</article-title><source>NPJ Biofilms Microbiomes</source><year>2017</year><volume>3</volume><fpage>27</fpage><pub-id pub-id-type="pmid">29104759</pub-id></element-citation></ref><ref id="B215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vande Voorde</surname><given-names>J</given-names></name><name><surname>Sabuncuo&#x0011f;lu</surname><given-names>S</given-names></name><name><surname>Noppen</surname><given-names>S</given-names></name><name><surname>Hofer</surname><given-names>A</given-names></name><name><surname>Ranjbarian</surname><given-names>F</given-names></name><name><surname>Fieuws</surname><given-names>S</given-names></name><name><surname>Balzarini</surname><given-names>J</given-names></name><name><surname>Liekens</surname><given-names>S</given-names></name></person-group><article-title>Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>13054</fpage><lpage>13065</lpage><pub-id pub-id-type="pmid">24668817</pub-id></element-citation></ref><ref id="B216"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geller</surname><given-names>LT</given-names></name><name><surname>Barzily-Rokni</surname><given-names>M</given-names></name><name><surname>Danino</surname><given-names>T</given-names></name><name><surname>Jonas</surname><given-names>OH</given-names></name><name><surname>Shental</surname><given-names>N</given-names></name><name><surname>Nejman</surname><given-names>D</given-names></name><name><surname>Gavert</surname><given-names>N</given-names></name><name><surname>Zwang</surname><given-names>Y</given-names></name><name><surname>Cooper</surname><given-names>ZA</given-names></name><name><surname>Shee</surname><given-names>K</given-names></name><etal/></person-group><article-title>Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine</article-title><source>Science</source><year>2017</year><volume>357</volume><fpage>1156</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">28912244</pub-id></element-citation></ref><ref id="B217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geller</surname><given-names>LT</given-names></name><name><surname>Straussman</surname><given-names>R</given-names></name></person-group><article-title>Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents</article-title><source>Mol Cell Oncol</source><year>2017</year><volume>5</volume><fpage>e1405139</fpage><pub-id pub-id-type="pmid">29404397</pub-id></element-citation></ref><ref id="B218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takasuna</surname><given-names>K</given-names></name><name><surname>Hagiwara</surname><given-names>T</given-names></name><name><surname>Hirohashi</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name><name><surname>Nagai</surname><given-names>E</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name><name><surname>Kamataki</surname><given-names>T</given-names></name></person-group><article-title>Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>3752</fpage><lpage>3757</lpage><pub-id pub-id-type="pmid">8706020</pub-id></element-citation></ref><ref id="B219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>BD</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Lane</surname><given-names>KT</given-names></name><name><surname>Scott</surname><given-names>JE</given-names></name><name><surname>Orans</surname><given-names>J</given-names></name><name><surname>Koo</surname><given-names>JS</given-names></name><name><surname>Venkatesh</surname><given-names>M</given-names></name><name><surname>Jobin</surname><given-names>C</given-names></name><name><surname>Yeh</surname><given-names>LA</given-names></name><name><surname>Mani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Alleviating cancer drug toxicity by inhibiting a bacterial enzyme</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>831</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">21051639</pub-id></element-citation></ref><ref id="B220"><label>220</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>H</given-names></name><name><surname>Kinouchi</surname><given-names>T</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Akimoto</surname><given-names>S</given-names></name><name><surname>Matsuda</surname><given-names>Y</given-names></name><name><surname>Ohnishi</surname><given-names>Y</given-names></name></person-group><article-title>Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil</article-title><source>Pharmacogenetics</source><year>1997</year><volume>7</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">9110360</pub-id></element-citation></ref><ref id="B221"><label>221</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Nagarsheth</surname><given-names>N</given-names></name><etal/></person-group><article-title>Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy</article-title><source>Cell</source><year>2017</year><volume>170</volume><fpage>548</fpage><lpage>563.e16</lpage><pub-id pub-id-type="pmid">28753429</pub-id></element-citation></ref><ref id="B222"><label>222</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehouritis</surname><given-names>P</given-names></name><name><surname>Cummins</surname><given-names>J</given-names></name><name><surname>Stanton</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>CT</given-names></name><name><surname>McCarthy</surname><given-names>FO</given-names></name><name><surname>Reid</surname><given-names>G</given-names></name><name><surname>Urbaniak</surname><given-names>C</given-names></name><name><surname>Byrne</surname><given-names>WL</given-names></name><name><surname>Tangney</surname><given-names>M</given-names></name></person-group><article-title>Local bacteria affect the efficacy of chemotherapeutic drugs</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>14554</fpage><pub-id pub-id-type="pmid">26416623</pub-id></element-citation></ref><ref id="B223"><label>223</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daill&#x000e8;re</surname><given-names>R</given-names></name><name><surname>V&#x000e9;tizou</surname><given-names>M</given-names></name><name><surname>Waldschmitt</surname><given-names>N</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Isnard</surname><given-names>C</given-names></name><name><surname>Poirier-Colame</surname><given-names>V</given-names></name><name><surname>Duong</surname><given-names>CPM</given-names></name><name><surname>Flament</surname><given-names>C</given-names></name><name><surname>Lepage</surname><given-names>P</given-names></name><name><surname>Roberti</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects</article-title><source>Immunity</source><year>2016</year><volume>45</volume><fpage>931</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">27717798</pub-id></element-citation></ref><ref id="B224"><label>224</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iida</surname><given-names>N</given-names></name><name><surname>Dzutsev</surname><given-names>A</given-names></name><name><surname>Stewart</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Bouladoux</surname><given-names>N</given-names></name><name><surname>Weingarten</surname><given-names>RA</given-names></name><name><surname>Molina</surname><given-names>DA</given-names></name><name><surname>Salcedo</surname><given-names>R</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Cramer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>967</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">24264989</pub-id></element-citation></ref><ref id="B225"><label>225</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuczma</surname><given-names>MP</given-names></name><name><surname>Ding</surname><given-names>ZC</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Habtetsion</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Hao</surname><given-names>Z</given-names></name><name><surname>Bryan</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Kochenderfer</surname><given-names>JN</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name></person-group><article-title>The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>111931</fpage><lpage>111942</lpage><pub-id pub-id-type="pmid">29340102</pub-id></element-citation></ref><ref id="B226"><label>226</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viaud</surname><given-names>S</given-names></name><name><surname>Saccheri</surname><given-names>F</given-names></name><name><surname>Mignot</surname><given-names>G</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Daill&#x000e8;re</surname><given-names>R</given-names></name><name><surname>Hannani</surname><given-names>D</given-names></name><name><surname>Enot</surname><given-names>DP</given-names></name><name><surname>Pfirschke</surname><given-names>C</given-names></name><name><surname>Engblom</surname><given-names>C</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>971</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">24264990</pub-id></element-citation></ref><ref id="B227"><label>227</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Effects of cyclophosphamide on immune system and gut microbiota in mice</article-title><source>Microbiol Res</source><year>2015</year><volume>171</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">25553830</pub-id></element-citation></ref><ref id="B228"><label>228</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulos</surname><given-names>CM</given-names></name><name><surname>Wrzesinski</surname><given-names>C</given-names></name><name><surname>Kaiser</surname><given-names>A</given-names></name><name><surname>Hinrichs</surname><given-names>CS</given-names></name><name><surname>Chieppa</surname><given-names>M</given-names></name><name><surname>Cassard</surname><given-names>L</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Boni</surname><given-names>A</given-names></name><name><surname>Muranski</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells <italic>via</italic> TLR4 signaling</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>2197</fpage><lpage>2204</lpage><pub-id pub-id-type="pmid">17657310</pub-id></element-citation></ref><ref id="B229"><label>229</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uribe-Herranz</surname><given-names>M</given-names></name><name><surname>Bittinger</surname><given-names>K</given-names></name><name><surname>Rafail</surname><given-names>S</given-names></name><name><surname>Guedan</surname><given-names>S</given-names></name><name><surname>Pierini</surname><given-names>S</given-names></name><name><surname>Tanes</surname><given-names>C</given-names></name><name><surname>Ganetsky</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>MA</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Tanyi</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Gut microbiota modulates adoptive cell therapy <italic>via</italic> CD8&#x003b1; dendritic cells and IL-12</article-title><source>JCI Insight</source><year>2018</year><fpage>3</fpage></element-citation></ref><ref id="B230"><label>230</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbonnel</surname><given-names>F</given-names></name><name><surname>Soularue</surname><given-names>E</given-names></name><name><surname>Coutzac</surname><given-names>C</given-names></name><name><surname>Chaput</surname><given-names>N</given-names></name><name><surname>Mateus</surname><given-names>C</given-names></name><name><surname>Lepage</surname><given-names>P</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name></person-group><article-title>Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?</article-title><source>Semin Immunopathol</source><year>2017</year><volume>39</volume><fpage>327</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">28093620</pub-id></element-citation></ref><ref id="B231"><label>231</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaput</surname><given-names>N</given-names></name><name><surname>Lepage</surname><given-names>P</given-names></name><name><surname>Coutzac</surname><given-names>C</given-names></name><name><surname>Soularue</surname><given-names>E</given-names></name><name><surname>Le Roux</surname><given-names>K</given-names></name><name><surname>Monot</surname><given-names>C</given-names></name><name><surname>Boselli</surname><given-names>L</given-names></name><name><surname>Routier</surname><given-names>E</given-names></name><name><surname>Cassard</surname><given-names>L</given-names></name><name><surname>Collins</surname><given-names>M</given-names></name><etal/></person-group><article-title>Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab</article-title><source>Ann Oncol</source><year>2017</year><volume>28</volume><fpage>1368</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">28368458</pub-id></element-citation></ref><ref id="B232"><label>232</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubin</surname><given-names>K</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Khanin</surname><given-names>R</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Ling</surname><given-names>L</given-names></name><name><surname>No</surname><given-names>D</given-names></name><name><surname>Gobourne</surname><given-names>A</given-names></name><name><surname>Littmann</surname><given-names>E</given-names></name><name><surname>Huttenhower</surname><given-names>C</given-names></name><etal/></person-group><article-title>Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>10391</fpage><pub-id pub-id-type="pmid">26837003</pub-id></element-citation></ref><ref id="B233"><label>233</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x000e9;tizou</surname><given-names>M</given-names></name><name><surname>Pitt</surname><given-names>JM</given-names></name><name><surname>Daill&#x000e8;re</surname><given-names>R</given-names></name><name><surname>Lepage</surname><given-names>P</given-names></name><name><surname>Waldschmitt</surname><given-names>N</given-names></name><name><surname>Flament</surname><given-names>C</given-names></name><name><surname>Rusakiewicz</surname><given-names>S</given-names></name><name><surname>Routy</surname><given-names>B</given-names></name><name><surname>Roberti</surname><given-names>MP</given-names></name><name><surname>Duong</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota</article-title><source>Science</source><year>2015</year><volume>350</volume><fpage>1079</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">26541610</pub-id></element-citation></ref><ref id="B234"><label>234</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivan</surname><given-names>A</given-names></name><name><surname>Corrales</surname><given-names>L</given-names></name><name><surname>Hubert</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Aquino-Michaels</surname><given-names>K</given-names></name><name><surname>Earley</surname><given-names>ZM</given-names></name><name><surname>Benyamin</surname><given-names>FW</given-names></name><name><surname>Lei</surname><given-names>YM</given-names></name><name><surname>Jabri</surname><given-names>B</given-names></name><name><surname>Alegre</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy</article-title><source>Science</source><year>2015</year><volume>350</volume><fpage>1084</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">26541606</pub-id></element-citation></ref><ref id="B235"><label>235</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gopalakrishnan</surname><given-names>V</given-names></name><name><surname>Spencer</surname><given-names>CN</given-names></name><name><surname>Nezi</surname><given-names>L</given-names></name><name><surname>Reuben</surname><given-names>A</given-names></name><name><surname>Andrews</surname><given-names>MC</given-names></name><name><surname>Karpinets</surname><given-names>TV</given-names></name><name><surname>Prieto</surname><given-names>PA</given-names></name><name><surname>Vicente</surname><given-names>D</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Wei</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">29097493</pub-id></element-citation></ref><ref id="B236"><label>236</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matson</surname><given-names>V</given-names></name><name><surname>Fessler</surname><given-names>J</given-names></name><name><surname>Bao</surname><given-names>R</given-names></name><name><surname>Chongsuwat</surname><given-names>T</given-names></name><name><surname>Zha</surname><given-names>Y</given-names></name><name><surname>Alegre</surname><given-names>ML</given-names></name><name><surname>Luke</surname><given-names>JJ</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><article-title>The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>104</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">29302014</pub-id></element-citation></ref><ref id="B237"><label>237</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Routy</surname><given-names>B</given-names></name><name><surname>Le Chatelier</surname><given-names>E</given-names></name><name><surname>Derosa</surname><given-names>L</given-names></name><name><surname>Duong</surname><given-names>CPM</given-names></name><name><surname>Alou</surname><given-names>MT</given-names></name><name><surname>Daill&#x000e8;re</surname><given-names>R</given-names></name><name><surname>Fluckiger</surname><given-names>A</given-names></name><name><surname>Messaoudene</surname><given-names>M</given-names></name><name><surname>Rauber</surname><given-names>C</given-names></name><name><surname>Roberti</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">29097494</pub-id></element-citation></ref><ref id="B238"><label>238</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostic</surname><given-names>AD</given-names></name><name><surname>Chun</surname><given-names>E</given-names></name><name><surname>Robertson</surname><given-names>L</given-names></name><name><surname>Glickman</surname><given-names>JN</given-names></name><name><surname>Gallini</surname><given-names>CA</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Clancy</surname><given-names>TE</given-names></name><name><surname>Chung</surname><given-names>DC</given-names></name><name><surname>Lochhead</surname><given-names>P</given-names></name><name><surname>Hold</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment</article-title><source>Cell Host Microbe</source><year>2013</year><volume>14</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">23954159</pub-id></element-citation></ref><ref id="B239"><label>239</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HE</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Cho</surname><given-names>NY</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Kang</surname><given-names>GH</given-names></name></person-group><article-title>Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma</article-title><source>Virchows Arch</source><year>2017</year><volume>471</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">28597080</pub-id></element-citation></ref><ref id="B240"><label>240</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiele Orberg</surname><given-names>E</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Tam</surname><given-names>AJ</given-names></name><name><surname>Dejea</surname><given-names>CM</given-names></name><name><surname>Destefano Shields</surname><given-names>CE</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>L</given-names></name><name><surname>Finard</surname><given-names>BB</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Fathi</surname><given-names>P</given-names></name><etal/></person-group><article-title>The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis</article-title><source>Mucosal Immunol</source><year>2017</year><volume>10</volume><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">27301879</pub-id></element-citation></ref><ref id="B241"><label>241</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>N</given-names></name><name><surname>Yuan</surname><given-names>R</given-names></name><name><surname>Prestwood</surname><given-names>TR</given-names></name><name><surname>Penny</surname><given-names>HL</given-names></name><name><surname>DiMaio</surname><given-names>MA</given-names></name><name><surname>Reticker-Flynn</surname><given-names>NE</given-names></name><name><surname>Krois</surname><given-names>CR</given-names></name><name><surname>Kenkel</surname><given-names>JA</given-names></name><name><surname>Pham</surname><given-names>TD</given-names></name><name><surname>Carmi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Normalizing Microbiota-Induced Retinoic Acid Deficiency Stimulates Protective CD8(+) T Cell-Mediated Immunity in Colorectal Cancer</article-title><source>Immunity</source><year>2016</year><volume>45</volume><fpage>641</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">27590114</pub-id></element-citation></ref><ref id="B242"><label>242</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremonesi</surname><given-names>E</given-names></name><name><surname>Governa</surname><given-names>V</given-names></name><name><surname>Garzon</surname><given-names>JFG</given-names></name><name><surname>Mele</surname><given-names>V</given-names></name><name><surname>Amicarella</surname><given-names>F</given-names></name><name><surname>Muraro</surname><given-names>MG</given-names></name><name><surname>Trella</surname><given-names>E</given-names></name><name><surname>Galati-Fournier</surname><given-names>V</given-names></name><name><surname>Oertli</surname><given-names>D</given-names></name><name><surname>D&#x000e4;ster</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Gut microbiota modulate T cell trafficking into human colorectal cancer</article-title><source>Gut</source><year>2018</year><comment>Epub ahead of print</comment></element-citation></ref><ref id="B243"><label>243</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mima</surname><given-names>K</given-names></name><name><surname>Sukawa</surname><given-names>Y</given-names></name><name><surname>Nishihara</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>ZR</given-names></name><name><surname>Yamauchi</surname><given-names>M</given-names></name><name><surname>Inamura</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>SA</given-names></name><name><surname>Masuda</surname><given-names>A</given-names></name><name><surname>Nowak</surname><given-names>JA</given-names></name><name><surname>Nosho</surname><given-names>K</given-names></name><etal/></person-group><article-title>Fusobacterium nucleatum and T Cells in Colorectal Carcinoma</article-title><source>JAMA Oncol</source><year>2015</year><volume>1</volume><fpage>653</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">26181352</pub-id></element-citation></ref><ref id="B244"><label>244</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Rhee</surname><given-names>KJ</given-names></name><name><surname>Albesiano</surname><given-names>E</given-names></name><name><surname>Rabizadeh</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Yen</surname><given-names>HR</given-names></name><name><surname>Huso</surname><given-names>DL</given-names></name><name><surname>Brancati</surname><given-names>FL</given-names></name><name><surname>Wick</surname><given-names>E</given-names></name><name><surname>McAllister</surname><given-names>F</given-names></name><etal/></person-group><article-title>A human colonic commensal promotes colon tumorigenesis <italic>via</italic> activation of T helper type 17 T cell responses</article-title><source>Nat Med</source><year>2009</year><volume>15</volume><fpage>1016</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">19701202</pub-id></element-citation></ref><ref id="B245"><label>245</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarnoutse</surname><given-names>R</given-names></name><name><surname>de Vos-Geelen</surname><given-names>JMPGM</given-names></name><name><surname>Penders</surname><given-names>J</given-names></name><name><surname>Boerma</surname><given-names>EG</given-names></name><name><surname>Warmerdam</surname><given-names>FARM</given-names></name><name><surname>Goorts</surname><given-names>B</given-names></name><name><surname>Olde Damink</surname><given-names>SWM</given-names></name><name><surname>Soons</surname><given-names>Z</given-names></name><name><surname>Rensen</surname><given-names>SSM</given-names></name><name><surname>Smidt</surname><given-names>ML</given-names></name></person-group><article-title>Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0</article-title><source>Int J Colorectal Dis</source><year>2017</year><volume>32</volume><fpage>1077</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">28444508</pub-id></element-citation></ref><ref id="B246"><label>246</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyton</surname><given-names>K</given-names></name><name><surname>Alverdy</surname><given-names>JC</given-names></name></person-group><article-title>The gut microbiota and gastrointestinal surgery</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2017</year><volume>14</volume><fpage>43</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">27729657</pub-id></element-citation></ref><ref id="B247"><label>247</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmann</surname><given-names>R</given-names></name><name><surname>Leonard</surname><given-names>D</given-names></name><name><surname>Delzenne</surname><given-names>N</given-names></name><name><surname>Kartheuser</surname><given-names>A</given-names></name><name><surname>Cani</surname><given-names>PD</given-names></name></person-group><article-title>Novel insight into the role of microbiota in colorectal surgery</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>738</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">28153961</pub-id></element-citation></ref><ref id="B248"><label>248</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sassone-Corsi</surname><given-names>M</given-names></name><name><surname>Raffatellu</surname><given-names>M</given-names></name></person-group><article-title>No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens</article-title><source>J Immunol</source><year>2015</year><volume>194</volume><fpage>4081</fpage><lpage>4087</lpage><pub-id pub-id-type="pmid">25888704</pub-id></element-citation></ref><ref id="B249"><label>249</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karrasch</surname><given-names>T</given-names></name><name><surname>Jobin</surname><given-names>C</given-names></name></person-group><article-title>Wound healing responses at the gastrointestinal epithelium: a close look at novel regulatory factors and investigative approaches</article-title><source>Z Gastroenterol</source><year>2009</year><volume>47</volume><fpage>1221</fpage><lpage>1229</lpage><pub-id pub-id-type="pmid">19960401</pub-id></element-citation></ref><ref id="B250"><label>250</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Liberman</surname><given-names>S</given-names></name><name><surname>Charlebois</surname><given-names>P</given-names></name><name><surname>Stein</surname><given-names>B</given-names></name><name><surname>Kaneva</surname><given-names>P</given-names></name><name><surname>Carli</surname><given-names>F</given-names></name><name><surname>Feldman</surname><given-names>LS</given-names></name></person-group><article-title>The impact of complications after elective colorectal resection within an enhanced recovery pathway</article-title><source>Tech Coloproctol</source><year>2018</year><volume>22</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">29508102</pub-id></element-citation></ref><ref id="B251"><label>251</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohigashi</surname><given-names>S</given-names></name><name><surname>Sudo</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>D</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name><name><surname>Onodera</surname><given-names>H</given-names></name></person-group><article-title>Significant changes in the intestinal environment after surgery in patients with colorectal cancer</article-title><source>J Gastrointest Surg</source><year>2013</year><volume>17</volume><fpage>1657</fpage><lpage>1664</lpage><pub-id pub-id-type="pmid">23807702</pub-id></element-citation></ref><ref id="B252"><label>252</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>DG</given-names></name><name><surname>Vieira</surname><given-names>AT</given-names></name><name><surname>Soares</surname><given-names>AC</given-names></name><name><surname>Pinho</surname><given-names>V</given-names></name><name><surname>Nicoli</surname><given-names>JR</given-names></name><name><surname>Vieira</surname><given-names>LQ</given-names></name><name><surname>Teixeira</surname><given-names>MM</given-names></name></person-group><article-title>The essential role of the intestinal microbiota in facilitating acute inflammatory responses</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>4137</fpage><lpage>4146</lpage><pub-id pub-id-type="pmid">15356164</pub-id></element-citation></ref><ref id="B253"><label>253</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stary</surname><given-names>L</given-names></name><name><surname>Mezerova</surname><given-names>K</given-names></name><name><surname>Skalicky</surname><given-names>P</given-names></name><name><surname>Zboril</surname><given-names>P</given-names></name><name><surname>Raclavsky</surname><given-names>V</given-names></name></person-group><article-title>Are we any closer to screening for colorectal cancer using microbial markers?A critical review</article-title><source>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</source><year>2017</year><volume>161</volume><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">29235578</pub-id></element-citation></ref><ref id="B254"><label>254</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flemer</surname><given-names>B</given-names></name><name><surname>Warren</surname><given-names>RD</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Cisek</surname><given-names>K</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Jeffery</surname><given-names>IB</given-names></name><name><surname>Hurley</surname><given-names>E</given-names></name><name><surname>O&#x02019;Riordain</surname><given-names>M</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name><name><surname>O&#x02019;Toole</surname><given-names>PW</given-names></name></person-group><article-title>The oral microbiota in colorectal cancer is distinctive and predictive</article-title><source>Gut</source><year>2017</year><comment>Epub ahead of print</comment></element-citation></ref><ref id="B255"><label>255</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>P</given-names></name><name><surname>Hold</surname><given-names>GL</given-names></name><name><surname>Flint</surname><given-names>HJ</given-names></name></person-group><article-title>The gut microbiota, bacterial metabolites and colorectal cancer</article-title><source>Nat Rev Microbiol</source><year>2014</year><volume>12</volume><fpage>661</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">25198138</pub-id></element-citation></ref></ref-list></back></article>
